Professor Neil R Poulter

Publications


Journals

  • Johnson T; Shaw-Hawkins S; Howard P; Lathrop M; Stanton A; Shields D; Poulter N; Sever P; et alMunroe PB; Caulfield M. (1 Oct 2010). A novel gene locus for blood pressure variability identified by genomewide association scanning in the Anglo-Scandinavian Cardiac Outcome Trial. JOURNAL OF HUMAN HYPERTENSION. 24:694-694. Author weblink.
  • Lindgren P; Buxton MJ; Kahan T; Poulter N; Dahlof B; Sever P; Wedel H; Jonsson B. (1 Nov 2004). Cost-effectiveness of reduction in cardiovascular outcomes with atorvastatin in patients with normal to mildly elevated cholesterol levels, treated for hypertension: The ASCOT-LLA study. VALUE IN HEALTH. 7:694-694. Author weblink DOI.
  • Afridi I; Canny J; Yao CH; Christensen B; Cooper RS; Kadiri S; Hill S; Kaplan N; et alKuschnir E; Lexchin J; Mendis S; Poulter N; Psaty BM; Rahn KH; Sheps SG; Whitworth J; Yach D; Bengoa R; Ramsay L; Kaplan N; Mendis S; Poulter N; Whitworth J. (1 Nov 2003). 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. JOURNAL OF HYPERTENSION. 21:1983-1992. Author weblink DOI.
  • Dahlof B; Sever P; Poulter N; Wedel H. (21 Jan 2006). ASCOT-BPLA - Reply. LANCET. 367:207-208. Author weblink DOI.
  • Poulter N. (1 Dec 2006). Are current therapies for hypertension achieving their goal?. JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM. 7:S3-S6. Author weblink DOI.
  • Poulter N; Williams B. (1 Nov 2001). Doxazosin for the management of hypertension: Implications of the findings of the ALLHAT Trial. AMERICAN JOURNAL OF HYPERTENSION. 14:1170-1171. Author weblink DOI.
  • Poulter N. (1 Oct 1999). Coronary heart disease is a multifactorial disease. AMERICAN JOURNAL OF HYPERTENSION. 12:92S-95S. Author weblink.
  • Primatesta P; Poulter N. (1 Jan 2000). Improving hypertension management in England since 1994. JOURNAL OF HYPERTENSION. 18:S2-S2. Author weblink.
  • Chang CL; Donaghy M; Poulter N. (2 Jan 1999). Migraine and stroke in young women: case-control study. BRITISH MEDICAL JOURNAL. 318:13-18. Author weblink.
  • Reeds PJ; Jackson AA; Picou D; Poulter N. (May 1978). Muscle mass and composition in malnourished infants and children and changes seen after recovery. Pediatr Res. 12:613-618. DOI.
  • Poulter N; Chang CL; Cuff A; Poulter C; Sever P; Thom S. (Jan 1994). Lipid profiles after the daily consumption of an oat-based cereal: a controlled crossover trial. Am J Clin Nutr. 59:66-69.
  • Poulter N; Sever P; Chang L. (17 Sep 1994). Low dose thiazide diuretic. May not lower blood pressure effectively. BMJ. 309:739.
  • Poulter N; Gabriel R; Porter KA; Bartlett C; Kershaw M; McKendrick GD; Venkataraman R. (Apr 1981). Acute interstitial nephritis complicating Legionnaires' Disease. Clin Nephrol. 15:216-220.
  • Poulter N; Gabriel R. (1979). Raynaud's phenomenon in hypertensive dialysis patients taking a sustained-release propranolol formulation. Curr Med Res Opin. 6:207-208. DOI.
  • Carvalho JJ; Baruzzi RG; Howard PF; Poulter N; Alpers MP; Franco LJ; Marcopito LF; Spooner VJ; et alDyer AR; Elliott P. (Sep 1989). Blood pressure in four remote populations in the INTERSALT Study. Hypertension. 14:238-246.
  • Deshmukh HA; Colhoun HM; Johnson T; McKeigue PM; Betteridge DJ; Durrington PN; Fuller JH; Livingstone S; et alCharlton-Menys V; Neil A; Poulter N; Sever P; Shields DC; Stanton AV; Chatterjee A; Hyde C; Calle RA; Demicco DA; Trompet S; Postmus I; Ford I; Jukema JW; Caulfield M; Hitman GA; on behalf of the CARDS, ASCOT, and PROSPER investigators. (May 2012). Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a). J Lipid Res. 53:1000-1011. DOI.
  • van Dieren S; Czernichow S; Chalmers J; Kengne AP; de Galan BE; Poulter N; Woodward M; Beulens JW; et alGrobbee DE; van der Schouw YT; Zoungas S. (May 2012). Weight changes and their predictors amongst 11 140 patients with type 2 diabetes in the ADVANCE trial. Diabetes Obes Metab. 14:464-469. DOI.
  • Woodward M; Patel A; Zoungas S; Liu L; Pan C; Poulter N; Januszewicz A; Tandon N; et alJoshi P; Heller S; Neal B; Chalmers J. (Dec 2011). Does glycemic control offer similar benefits among patients with diabetes in different regions of the world? Results from the ADVANCE trial. Diabetes Care. 34:2491-2495. DOI.
  • Chalmers J; Harrap S; Narkiewicz K; Poulter N; Redon J; Zanchetti A; Mancia G. (Dec 2010). Issues in the development of new combinations of blood pressure lowering drugs. J Hypertens. 28:2494-2496. DOI.
  • Batty GD; Li Q; Czernichow S; Neal B; Zoungas S; Huxley R; Patel A; de Galan BE; et alWoodward M; Hamet P; Harrap SB; Poulter N; Chalmers J; ADVANCE Collaborative Group. (30 Nov 2010). Erectile dysfunction and later cardiovascular disease in men with type 2 diabetes: prospective cohort study based on the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation) trial. J Am Coll Cardiol. 56:1908-1913. DOI.
  • Lee CC; Stolk RP; Adler AI; Patel A; Chalmers J; Neal B; Poulter N; Harrap S; et alWoodward M; Marre M; Grobbee DE; Beulens JW; AdRem project team and ADVANCE management committee. (Oct 2010). Association between alcohol consumption and diabetic retinopathy and visual acuity-the AdRem Study. Diabet Med. 27:1130-1137. DOI.
  • Glasziou PP; Clarke P; Alexander J; Rajmokan M; Beller E; Woodward M; Chalmers J; Poulter N; et alPatel A. (20 Sep 2010). Cost-effectiveness of lowering blood pressure with a fixed combination of perindopril and indapamide in type 2 diabetes mellitus: an ADVANCE trial-based analysis. Med J Aust. 193:320-324.
  • Zoungas S; Chalmers J; Kengne AP; Pillai A; Billot L; de Galan B; Marre M; Neal B; et alHarrap S; Poulter N; Patel A. (Aug 2010). The efficacy of lowering glycated haemoglobin with a gliclazide modified release-based intensive glucose lowering regimen in the ADVANCE trial. Diabetes Res Clin Pract. 89:126-133. DOI.
  • Ninomiya T; Zoungas S; Neal B; Woodward M; Patel A; Perkovic V; Cass A; Cooper M; et alGrobbee D; Hamet P; Harrap S; Liu L; Mancia G; Mogensen CE; Poulter N; Rodgers A; Williams B; MacMahon S; Chalmers J; ADVANCE Collaborative Group. (Jun 2010). Efficacy and safety of routine blood pressure lowering in older patients with diabetes: results from the ADVANCE trial. J Hypertens. 28:1141-1149.
  • Zoungas S; de Galan BE; Ninomiya T; Grobbee D; Hamet P; Heller S; MacMahon S; Marre M; et alNeal B; Patel A; Woodward M; Chalmers J; ADVANCE Collaborative Group; Cass A; Glasziou P; Harrap S; Lisheng L; Mancia G; Pillai A; Poulter N; Perkovic V; Travert F. (Nov 2009). Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial. Diabetes Care. 32:2068-2074. DOI.
  • Ninomiya T; Perkovic V; de Galan BE; Zoungas S; Pillai A; Jardine M; Patel A; Cass A; et alNeal B; Poulter N; Mogensen CE; Cooper M; Marre M; Williams B; Hamet P; Mancia G; Woodward M; Macmahon S; Chalmers J; ADVANCE Collaborative Group. (Aug 2009). Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol. 20:1813-1821. DOI.
  • de Galan BE; Perkovic V; Ninomiya T; Pillai A; Patel A; Cass A; Neal B; Poulter N; et alHarrap S; Mogensen CE; Cooper M; Marre M; Williams B; Hamet P; Mancia G; Woodward M; Glasziou P; Grobbee DE; MacMahon S; Chalmers J; ADVANCE Collaborative Group. (Apr 2009). Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrol. 20:883-892. DOI.
  • Lindgren P; Kahan T; Poulter N; Buxton M; Svarvar P; Dahlöf B; Jonsson B; ASCOT investigators. (Mar 2007). Utility loss and indirect costs following cardiovascular events in hypertensive patients: the ASCOT health economic substudy. Eur J Health Econ. 8:25-30. DOI.
  • Poulter N; Hughes AD; Williams B; Brady AJ; McInnes G; British Hypertension Society. (Jun 2006). Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers. A mini-symposium held at the British Hypertension Society Meeting, September 2005. J Renin Angiotensin Aldosterone Syst. 7:104-121. DOI.
  • Erdine S; Ari O; Zanchetti A; Cifkova R; Fagard R; Kjeldsen S; Mancia G; Poulter N; et alRahn KH; Rodicio JL; Ruilope LM; Staessen J; van Zwieten P; Waeber B; Williams B. (Jun 2006). ESH-ESC guidelines for the management of hypertension. Herz. 31:331-338. DOI.
  • Poulter N. (Jan 1991). Management of multiple risk factors for coronary heart disease in patients with hypertension. Am Heart J. 121:246-249.
  • Chang CL; Shipley M; Marmot M; Poulter N. (Jul 2004). Lower ambient temperature was associated with an increased risk of hospitalization for stroke and acute myocardial infarction in young women. J Clin Epidemiol. 57:749-757. DOI.
  • Poulter N; Marmot MG. (Dec 1992). Hypertension and the probability of an incapacitating event over a defined period: impact of treatment. Eur Heart J. 13 Suppl H:39-44.
  • Cifkova R; Erdine S; Fagard R; Farsang C; Heagerty AM; Kiowski W; Kjeldsen S; Lüscher T; et alMallion JM; Mancia G; Poulter N; Rahn KH; Rodicio JL; Ruilope LM; van Zwieten P; Waeber B; Williams B; Zanchetti A; ESH/ESC Hypertension Guidelines Committee. (Oct 2003). Practice guidelines for primary care physicians: 2003 ESH/ESC hypertension guidelines. J Hypertens. 21:1779-1786. DOI.
  • Poulter N. (Aug 2000). Other drug treatments: the evidence. Proc Nutr Soc. 59:425-426.
  • Poulter N. (Oct 1999). Coronary heart disease is a multifactorial disease. Am J Hypertens. 12:92S-95S.
  • Bost L; Primatesta P; Dong W; Poulter N. (Feb 1999). Blood lead and blood pressure: evidence from the Health Survey for England 1995. J Hum Hypertens. 13:123-128.
  • Jafar TH; Islam M; Bux R; Poulter N; Hatcher J; Chaturvedi N; Ebrahim S; Cosgrove P. (11 Oct 2011). Cost-Effectiveness of Community-Based Strategies for Blood Pressure Control in a Low-Income Developing Country Findings From a Cluster-Randomized, Factorial-Controlled Trial. CIRCULATION. 124:1615-1625. Author weblink DOI.
  • HENNEY AM; ADISESHIAH M; POULTER N; MACSWEENEY STR; GREENHALGH RM; POWELL JT. (23 Jan 1993). ABDOMINAL AORTIC-ANEURYSM - REPORT OF A MEETING OF PHYSICIANS AND SCIENTISTS, UNIVERSITY-COLLEGE-LONDON MEDICAL-SCHOOL. LANCET. 341:215-220. Author weblink DOI.
  • POWELL J; EDWARDS R; WORRELL PC; GREENHALGH RM; FRANKS PJ; POULTER N. (1 Apr 1994). IMPORTANT RISK-FACTORS IN THE DEVELOPMENT OF PERIPHERAL ARTERIAL-DISEASE IN SMOKERS. BRITISH JOURNAL OF SURGERY. 81:607-608. Author weblink.
  • Sever PS; Dahlof B; Poulter N; Wedel H. (7 Jun 2003). ASCOT-LLA: questions about the benefits of atorvastatin - Reply. LANCET. 361:1986-1987. Author weblink DOI.
  • Li Q; Chalmers J; Czernichow S; Neal B; Taylor BA; Zoungas S; Poulter N; Woodward M; et alPatel A; de Galan B; Batty GD. (1 Nov 2010). Oral disease and subsequent cardiovascular disease in people with type 2 diabetes: a prospective cohort study based on the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation (ADVANCE) trial. DIABETOLOGIA. 53:2320-2327. Author weblink DOI.
  • Poole-Wilson P; Cleland J; Hubbard W; Sutton G; Pittard J; Osborne C; Long C; Ingham S; et alRobinson P; Ball S; Hampton J; Poulter N; Murray G; Travill C; Bain RJ; Baksi A; Baxter RH; Been A; Berkin KE; Blackwood R; Blandford RL; Boyle RM; Buchalter M; Campbell R; Challenor V; Cheadle B; Coats A; Collins P; Cowan C; Creamer J; Dancy CM; Davies J; Davies R; Ehsanulliah M; Elder A; Fowler JM; Fulcher RA; Ghosh MK; Greenbaum RA; Greenwood TW; Grimmer SEM; Harvey J; Heller A; Henderson AN; Hendra T; Hendrey WG; Hogan J; Hollinrake K; Holt P; Hutton I; Jones A; Jones I; Levy R; Lewis P; Lewis R; McCulloch A; McMahon DG; McMurray JJ; McNeil GP; Mondal BK; Morant AJ; Murphy J; Murray RG; Northcote RJ; Patterson D; Peaston MJT; Petri MP; Pippen CAR; Pitts-Crick J; Puri RK; Raj MVJ; Rao SK; Reid C; Reith SBM; Rodger JC; Rozcovec A; Sethi P; Shapiro L; Silas J; Skehan JD; Smith D; Smith RH; Terry G; Thomas P; Timmis S; Waller LD; Walton S; Whale RJ; Wijayawardhana UD; Wilson JL. (1 Mar 1998). Clinical outcome with enalapril in symptomatic chronic heart failure; a dose comparison. EUROPEAN HEART JOURNAL. 19:481-489. Author weblink.
  • Chapman N; Mayet J; Chang L; Foale R; Thom S; Poulter N. (1 Jun 1998). Ethnic differences in ECG detection of left ventricular hypertrophy. JOURNAL OF HYPERTENSION. 16:S199-S199. Author weblink.
  • Du X; Ninomiya T; de Galan B; Abadir E; Chalmers J; Pillai A; Woodward M; Cooper M; et alHarrap S; Hamet P; Poulter N; Lip GYH; Patel A. (1 May 2009). Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study. EUROPEAN HEART JOURNAL. 30:1128-1135. Author weblink DOI.
  • Poulter N; Chang CL; McGregor A; Spector T. (1 Oct 1998). Differences in birthweight between twins and subsequent differences in BP. HYPERTENSION. 32:794-794. Author weblink.
  • Jafar TH; Hatcher J; Poulter N; Islam M; Hashmi S; Qadri Z; Bux R; Khan A; et alJafary FH; Hameed A; Khan A; Badruddin SH; Chaturvedi N. (3 Nov 2009). Community-Based Interventions to Promote Blood Pressure Control in a Developing Country A Cluster Randomized Trial. ANNALS OF INTERNAL MEDICINE. 151:593-W195. Author weblink.
  • Zoungas S; Chalmers J; Ninomiya T; Li Q; Cooper ME; Colagiuri S; Fulcher G; de Galan BE; et alHarrap S; Hamet P; Heller S; MacMahon S; Marre M; Poulter N; Travert F; Patel A; Neal B; Woodward M. (1 Mar 2012). Association of HbA(1c) levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. DIABETOLOGIA. 55:636-643. Author weblink DOI.
  • de Galan BE; Zoungas S; Chalmers J; Anderson C; Dufouil C; Pillai A; Cooper M; Grobbee DE; et alHackett M; Hamet P; Heller SR; Lisheng L; MacMahon S; Mancia G; Neal B; Pan CY; Patel A; Poulter N; Travert F; Woodward M. (1 Nov 2009). Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. DIABETOLOGIA. 52:2328-2336. Author weblink DOI.
  • Wood D; Wray R; Poulter N; Williams B; Kirby M; Patel V; Durrington P; Reckless J; et alDavis M; Sivers F; Potter J. (1 Dec 2005). JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. HEART. 91. Author weblink DOI.
  • Rodgers A; Patel A; Berwanger O; Bots M; Grimm R; Grobbee DE; Jackson R; Neal B; et alNeaton J; Poulter N; Rafter N; Raju PK; Reddy S; Thom S; Vander Hoorn S; Webster R. (25 May 2011). An International Randomised Placebo-Controlled Trial of a Four-Component Combination Pill ("Polypill") in People with Raised Cardiovascular Risk. PLOS ONE. 6. DOI.
  • Jafar TH; Islam M; Poulter N; Hatcher J; Schmid CH; Levey AS; Chaturvedi N. (15 Mar 2005). Children in south Asia have higher body mass-adjusted blood pressure levels than white children in the United States - A comparative study. CIRCULATION. 111:1291-1297. Author weblink DOI.
  • Jafar TH; Islam M; Hatcher J; Hashmi S; Bux R; Khan A; Poulter N; Badruddin S; et alChaturvedi N. (7 Jun 2010). Community based lifestyle intervention for blood pressure reduction in children and young adults in developing country: cluster randomised controlled trial. BRITISH MEDICAL JOURNAL. 340. DOI.
  • Poulter N; Khaw KT; Hopwood BE; Mugambi M; Peart WS; Sever PS. (1984). Salt and blood pressure in various populations. J Cardiovasc Pharmacol. 6 Suppl 1:S197-S203.
  • POULTER N; KHAW KT; HOPWOOD BEC; MUGAMBI M; PEART WS; ROSE G; SEVER PS. (1 Jan 1984). BLOOD-PRESSURE AND ITS CORRELATES IN AN AFRICAN TRIBE IN URBAN AND RURAL ENVIRONMENTS. JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH. 38:181-185. Author weblink DOI.
  • Poulter N; Khaw KT; Hopwood BE; Mugambi M; Peart WS; Rose G; Sever PS. (Nov 1984). Blood pressure and associated factors in a rural Kenyan community. Hypertension. 6:810-813.
  • Poulter N; Thompson AV; Sever PS. (1987). A double-blind, placebo-controlled, crossover trial to investigate the additive hypotensive effect of a diuretic (mefruside) to that produced by nifedipine. J Cardiovasc Pharmacol. 10 Suppl 10:S53-S56.
  • Thom S; Bunker J; Callister W; Poulter N; Sever P; Zographos D. (Dec 1989). Multiple risk factor evaluation in a hypertension clinic. J Hypertens Suppl. 7:S330-S331.
  • SHAHI M; THOM S; POULTER N; SEVER PS; FOALE RA. (25 Aug 1990). REGRESSION OF HYPERTENSIVE LEFT-VENTRICULAR HYPERTROPHY AND LEFT-VENTRICULAR DIASTOLIC FUNCTION. LANCET. 336:458-461. Author weblink DOI.
  • Shahi M; Thom S; Poulter N; Sever PS; Foale RA. (Feb 1991). Determinants of left ventricular filling in hypertension. J Hum Hypertens. 5:27-34.
  • SHAHI M; THOM S; POULTER N; SEVER PS; FOALE RA. (1 Sep 1991). THE EFFECTS OF BLOOD-PRESSURE REDUCTION ON ABNORMAL LEFT-VENTRICULAR DIASTOLIC FUNCTION IN HYPERTENSIVE PATIENTS. EUROPEAN HEART JOURNAL. 12:974-979. Author weblink.
  • Chapman N; Mayet J; Ozkor M; Foale R; Thom S; Poulter N. (Jun 2000). Ethnic and gender differences in electrocardiographic QT length and QT dispersion in hypertensive subjects. J HUM HYPERTENS. 14:403-405.
  • Sever P; Dahlöf B; Poulter N; Wedel H; Beevers G; Caulfield M; Collins R; Kjeldsen S; et alKristinsson A; McInnes G; Mehlsen J; Nieminem M; O'Brien E; Ostergren J; ASCOT Steering Committee Members. (Dec 2006). Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial. Eur Heart J. 27:2982-2988. DOI.
  • Falaschetti E; Chaudhury M; Mindell J; Poulter N. (Mar 2009). Continued improvement in hypertension management in England: results from the Health Survey for England 2006. Hypertension. 53:480-486. DOI.
  • Stettler C; Witt N; Tapp RJ; Thom S; Allemann S; Tillin T; Stanton A; O'Brien E; et alPoulter N; Gallimore JR; Hughes AD; Chaturvedi N. (1 Jun 2009). Serum Amyloid A, C-Reactive Protein, and Retinal Microvascular Changes in Hypertensive Diabetic and Nondiabetic Individuals An Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) substudy. DIABETES CARE. 32:1098-1100. Author weblink DOI.
  • Falaschetti E; Campbell NR; Mohan S; Poulter N. (Jul 2009). Implementation of pay for performance policy in England. Hypertension. 54:e5. DOI.
  • Thom S; Stettler C; Stanton A; Witt N; Tapp R; Chaturvedi N; Allemann S; Mayet J; et alSever P; Poulter N; O'Brien E; Hughes A. (Aug 2009). Differential effects of antihypertensive treatment on the retinal microcirculation: an anglo-scandinavian cardiac outcomes trial substudy. Hypertension. 54:405-408. DOI.
  • Manisty C; Mayet J; Tapp RJ; Sever PS; Poulter N; McG Thom SA; Hughes AD; ASCOT Investigators. (Nov 2009). Atorvastatin treatment is associated with less augmentation of the carotid pressure waveform in hypertension: a substudy of the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT). Hypertension. 54:1009-1013. DOI.
  • Mindell J; Aresu M; Zaninotto P; Falaschetti E; Poulter N. (Nov 2011). Improving lipid profiles and increasing use of lipid-lowering therapy in England: results from a national cross-sectional survey - 2006. Clin Endocrinol (Oxf). 75:621-627. DOI.
  • Saxena R; Elbers CC; Guo Y; Peter I; Gaunt TR; Mega JL; Lanktree MB; Tare A; et alCastillo BA; Li YR; Johnson T; Bruinenberg M; Gilbert-Diamond D; Rajagopalan R; Voight BF; Balasubramanyam A; Barnard J; Bauer F; Baumert J; Bhangale T; Böhm BO; Braund PS; Burton PR; Chandrupatla HR; Clarke R; Cooper-DeHoff RM; Crook ED; Davey-Smith G; Day IN; de Boer A; de Groot MC; Drenos F; Ferguson J; Fox CS; Furlong CE; Gibson Q; Gieger C; Gilhuijs-Pederson LA; Glessner JT; Goel A; Gong Y; Grant SF; Grobbee DE; Hastie C; Humphries SE; Kim CE; Kivimaki M; Kleber M; Meisinger C; Kumari M; Langaee TY; Lawlor DA; Li M; Lobmeyer MT; Maitland-van der Zee AH; Meijs MF; Molony CM; Morrow DA; Murugesan G; Musani SK; Nelson CP; Newhouse SJ; O'Connell JR; Padmanabhan S; Palmen J; Patel SR; Pepine CJ; Pettinger M; Price TS; Rafelt S; Ranchalis J; Rasheed A; Rosenthal E; Ruczinski I; Shah S; Shen H; Silbernagel G; Smith EN; Spijkerman AW; Stanton A; Steffes MW; Thorand B; Trip M; van der Harst P; van der A DL; van Iperen EP; van Setten J; van Vliet-Ostaptchouk JV; Verweij N; Wolffenbuttel BH; Young T; Zafarmand MH; Zmuda JM; Look AHEAD Research Group; DIAGRAM consortium; Boehnke M; Altshuler D; McCarthy M; Kao WH; Pankow JS; Cappola TP; Sever P; Poulter N; Caulfield M; Dominiczak A; Shields DC; Bhatt DL; Zhang L; Curtis SP; Danesh J; Casas JP; van der Schouw YT; Onland-Moret NC; Doevendans PA; Dorn GW; Farrall M; FitzGerald GA; Hamsten A; Hegele R; Hingorani AD; Hofker MH; Huggins GS; Illig T; Jarvik GP; Johnson JA; Klungel OH; Knowler WC; Koenig W; März W; Meigs JB; Melander O; Munroe PB; Mitchell BD; Bielinski SJ; Rader DJ; Reilly MP; Rich SS; Rotter JI; Saleheen D; Samani NJ; Schadt EE; Shuldiner AR; Silverstein R; Kottke-Marchant K; Talmud PJ; Watkins H; Asselbergs FW; de Bakker PI; McCaffery J; Wijmenga C; Sabatine MS; Wilson JG; Reiner A; Bowden DW; Hakonarson H; Siscovick DS; Keating BJ. (9 Mar 2012). Large-scale gene-centric meta-analysis across 39 studies identifies type 2 diabetes loci. Am J Hum Genet. 90:410-425. DOI.
  • Hillis GS; Woodward M; Rodgers A; Chow CK; Li Q; Zoungas S; Patel A; Webster R; et alBatty GD; Ninomiya T; Mancia G; Poulter NR; Chalmers J. (29 Jan 2012). Resting heart rate and the risk of death and cardiovascular complications in patients with type 2 diabetes mellitus. Diabetologia. DOI.
  • Poulter NR. (Dec 2011). A new dimension in hypertension management with the amlodipine/perindopril combination. J Hypertens. 29 Suppl 1:S15-S21. DOI.
  • Patel A; MacMahon S; Chalmers J; Neal B; Billot L; Woodward M; Marre M; Cooper M; et alGlaziou P; Grobbee D; Hamet P; Harrap S; Heller S; Liu L; Mancia G; Mogensen CE; Pan C; Poulter N; Rodgers A; Williams B; Bompoint S; de Galan BE; Joshi R; Travert F. (2008). Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. New England Journal of Medicine. 358:2560-2572.
  • Johnson T; Gaunt TR; Newhouse SJ; Padmanabhan S; Tomaszewski M; Kumari M; Morris RW; Tzoulaki I; et alO'Brien ET; Poulter NR; Sever P; Shields DC; Thom S; Wannamethee SG; Whincup PH; Brown MJ; Connell JM; Dobson RJ; Howard PJ; Mein CA; Onipinla A; Shaw-Hawkins S; Zhang Y; Davey Smith G; Day IN; Lawlor DA; Goodall AH; Cardiogenics Consortium; Fowkes FG; Abecasis GR; Elliott P; Gateva V; Global BPgen Consortium; Braund PS; Burton PR; Nelson CP; Tobin MD; van der Harst P; Glorioso N; Neuvrith H; Salvi E; Staessen JA; Stucchi A; Devos N; Jeunemaitre X; Plouin PF; Tichet J; Juhanson P; Org E; Putku M; Sõber S; Veldre G; Viigimaa M; Levinsson A; Rosengren A; Thelle DS; Hastie CE; Hedner T; Lee WK; Melander O; Wahlstrand B; Hardy R; Wong A; Cooper JA; Palmen J; Chen L; Stewart AF; Wells GA; Westra HJ; Wolfs MG; Clarke R; Franzosi MG; Goel A; Hamsten A; Lathrop M; Peden JF; Seedorf U; Watkins H; Ouwehand WH; Sambrook J; Stephens J; Casas JP; Drenos F; Holmes MV; Kivimaki M; Shah S; Shah T; Talmud PJ; Whittaker J; Wallace C; Delles C; Laan M; Kuh D; Humphries SE; Nyberg F; Cusi D; Roberts R; Newton-Cheh C; Franke L; Stanton AV; Dominiczak AF; Farrall M; Hingorani AD; Samani NJ; Caulfield MJ; Munroe PB. (9 Dec 2011). Blood pressure loci identified with a gene-centric array. Am J Hum Genet. 89:688-700. DOI.
  • Gupta AK; Chang CL; Dahlof B; Poulter NR; Sever PS. (1 Oct 2011). Cardiovascular and all-cause mortality outcomes among hypertensive patients with moderate renal dysfunction in the ASCOT-LLA, and its extended follow-up. JOURNAL OF HUMAN HYPERTENSION. 25:633-634.
  • Gupta AK; Nasothimiou EG; Chang CL; Sever PS; Dahlöf B; Poulter NR; ASCOT investigators. (Oct 2011). Baseline predictors of resistant hypertension in the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT): a risk score to identify those at high-risk. J Hypertens. 29:2004-2013. DOI.
  • Sever PS; Chang CL; Gupta AK; Whitehouse A; Poulter NR; ASCOT Investigators. (Oct 2011). The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the U.K. Eur Heart J. 32:2525-2532. DOI.
  • Sever PS; Poulter NR; Chang CL; Hingorani A; Thom SA; Hughes AD; Welsh P; Sattar N; et alASCOT Investigators. (Feb 2012). Evaluation of C-reactive protein prior to and on-treatment as a predictor of benefit from atorvastatin: observations from the Anglo-Scandinavian Cardiac Outcomes Trial. Eur Heart J. 33:486-494. DOI.
  • Gupta AK; Prieto-Merino D; Dahlöf B; Sever PS; Poulter NR; ASCOT Investigators. (Aug 2011). Metabolic syndrome, impaired fasting glucose and obesity, as predictors of incident diabetes in 14 120 hypertensive patients of ASCOT-BPLA: comparison of their relative predictability using a novel approach. Diabet Med. 28:941-947. DOI.
  • Chapman N; Chang CL; Caulfield M; Dahlöf B; Feder G; Sever PS; Poulter NR. (2011). Ethnic variations in lipid-lowering in response to a statin (EVIREST): a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Ethn Dis. 21:150-157.
  • Poulter NR. (Jul 2011). Current and projected prevalence of arterial hypertension in sub-Saharan Africa by sex, age and habitat: an estimate from population studies. J Hypertens. 29:1281-1282. DOI.
  • de la Iglesia B; Potter JF; Poulter NR; Robins MM; Skinner J. (1 Mar 2011). Advantages of QRISK2 (2010): the key issue is ethnicity and extent of reallocation reply. HEART. 97:515-516. DOI.
  • Collier DJ; Poulter NR; Dahlöf B; Sever PS; Wedel H; Buch J; Caulfield MJ; ASCOT Investigators. (Mar 2011). Impact of atorvastatin among older and younger patients in the Anglo-Scandinavian Cardiac Outcomes Trial Lipid-Lowering Arm. J Hypertens. 29:592-599. DOI.
  • Collier DJ; Poulter NR; Dahlöf B; Sever PS; Wedel H; Buch J; Caulfield MJ; ASCOT Investigators. (Mar 2011). Impact of amlodipine-based therapy among older and younger patients in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). J Hypertens. 29:583-591. DOI.
  • Manisty C; Mayet J; Tapp RJ; Parker KH; Sever P; Poulter NR; Thom SA; Hughes AD; et alASCOT Investigators. (29 Jun 2010). Wave reflection predicts cardiovascular events in hypertensive individuals independent of blood pressure and other cardiovascular risk factors: an ASCOT (Anglo-Scandinavian Cardiac Outcome Trial) substudy. J Am Coll Cardiol. 56:24-30. DOI.
  • de la Iglesia B; Potter JF; Poulter NR; Robins MM; Skinner J. (Mar 2011). Performance of the ASSIGN cardiovascular disease risk score on a UK cohort of patients from general practice. Heart. 97:491-499. DOI.
  • Gupta AK; Poulter NR. (12 Oct 2010). The concept of the metabolic syndrome is it dead yet?. J Am Coll Cardiol. 56:1355-1356. DOI.
  • Gupta AK; Poulter NR; Dobson J; Eldridge S; Cappuccio FP; Caulfield M; Collier D; Cruickshank JK; et alSever PS; Feder G; ASCOT. (Sep 2010). Ethnic differences in blood pressure response to first and second-line antihypertensive therapies in patients randomized in the ASCOT Trial. Am J Hypertens. 23:1023-1030. DOI.
  • Lindgren P; Eriksson J; Buxton M; Kahan T; Poulter NR; Dahlof B; Sever PS; Wedel H; et alJonsson B. (1 Aug 2010). The economic consequences of non-adherence to lipid-lowering therapy: results from the Anglo-Scandinavian-Cardiac Outcomes Trial. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE. 64:1228-1234. Author weblink DOI.
  • Robinson TG; Potter JF; Ford GA; Bulpitt CJ; Chernova J; Jagger C; James MA; Knight J; et alMarkus HS; Mistri AK; Poulter NR; COSSACS Investigators. (Aug 2010). Effects of antihypertensive treatment after acute stroke in the Continue or Stop Post-Stroke Antihypertensives Collaborative Study (COSSACS): a prospective, randomised, open, blinded-endpoint trial. Lancet Neurol. 9:767-775. DOI.
  • Gupta AK; Dahlof B; Sever PS; Poulter NR; Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm Investigators. (Jul 2010). Metabolic syndrome, independent of its components, is a risk factor for stroke and death but not for coronary heart disease among hypertensive patients in the ASCOT-BPLA. Diabetes Care. 33:1647-1651. DOI.
  • Tapp RJ; Sharp A; Stanton AV; O'Brien E; Chaturvedi N; Poulter NR; Sever PS; Thom SA; et alHughes AD; Mayet J; ASCOT Investigators. (27 Apr 2010). Differential effects of antihypertensive treatment on left ventricular diastolic function: an ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial) substudy. J Am Coll Cardiol. 55:1875-1881. DOI.
  • Rothwell PM; Howard SC; Dolan E; O'Brien E; Dobson JE; Dahlöf B; Sever PS; Poulter NR. (13 Mar 2010). Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet. 375:895-905. DOI.
  • Rothwell PM; Howard SC; Dolan E; O'Brien E; Dobson JE; Dahlöf B; Poulter NR; Sever PS; et alASCOT-BPLA and MRC Trial Investigators. (May 2010). Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol. 9:469-480. DOI.
  • Poulter NR; Dobson JE; Sever PS; Dahlof B; Campbell NRC. (2 Mar 2010). Elevated Heart Rate in Hypertension A Target for Treatment? Reply. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. 55:931-932. Author weblink DOI.
  • Gupta AK; Arshad S; Poulter NR. (Feb 2010). Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension. 55:399-407. DOI.
  • Sharp AS; Tapp RJ; Thom SA; Francis DP; Hughes AD; Stanton AV; Zambanini A; O'Brien E; et alChaturvedi N; Lyons S; Byrd S; Poulter NR; Sever PS; Mayet J; ASCOT Investigators. (Mar 2010). Tissue Doppler E/E' ratio is a powerful predictor of primary cardiac events in a hypertensive population: an ASCOT substudy. Eur Heart J. 31:747-752. DOI.
  • Prieto-Merino D; Gupta AK; Dobson J; Chang CL; Mastorantonakis S; Sever PS; Dahlof B; Wedel H; et alPocock S; Poulter NR. (1 Oct 2009). ASCORE: an up-to-date cardiovascular risk score for hypertensive patients reflecting contemporary clinical practices developed using the ASCOT trial database. JOURNAL OF HUMAN HYPERTENSION. 23:695-695. Author weblink.
  • Poulter NR; Dobson JE; Sever PS; Dahlof B; Wedel H; Campbell NRC. (22 Sep 2009). Baseline Heart Rate, Antihypertensive Treatment, and Prevention of Cardiovascular Outcomes in ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial). JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. 54:1154-1161. Author weblink DOI.
  • Poulter NR. (1 May 2009). Blood pressure and glucose control in subjects with diabetes: new analyses from ADVANCE. JOURNAL OF HYPERTENSION. 27:S3-S8. Author weblink DOI.
  • Shahab L; Mindell J; Poulter NR; West R. (Feb 2010). Hypertension and its identification among current, past and never smokers in an English population sample. Eur J Cardiovasc Prev Rehabil. 17:63-70. DOI.
  • Wilson SL; Scullard G; Fidler SJ; Weber JN; Poulter NR. (Jul 2009). Effects of HIV status and antiretroviral therapy on blood pressure. HIV Med. 10:388-394. DOI.
  • Sever PS; Poulter NR; Dahlof B; Wedel H. (1 May 2009). Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension. JOURNAL OF HYPERTENSION. 27:947-954. Author weblink DOI.
  • Lindgren P; Buxton M; Kahan T; Poulter NR; Dahlöf B; Sever PS; Wedel H; Jönsson B; et alASCOT investigators. (2009). The lifetime cost effectiveness of amlodipine-based therapy plus atorvastatin compared with atenolol plus atorvastatin, amlodipine-based therapy alone and atenolol-based therapy alone: results from ASCOT1. Pharmacoeconomics. 27:221-230.
  • White SL; Perkovic V; Cass A; Chang CL; Poulter NR; Spector T; Haysom L; Craig JC; et alSalmi IA; Chadban SJ; Huxley RR. (Aug 2009). Is low birth weight an antecedent of CKD in later life? A systematic review of observational studies. Am J Kidney Dis. 54:248-261. DOI.
  • Sever PS; Poulter NR; Mastorantonakis S; Chang CL; Dahlof B; Wedel H; ASCOT Investigators. (26 Jun 2009). Coronary heart disease benefits from blood pressure and lipid-lowering. Int J Cardiol. 135:218-222. DOI.
  • Ostergren J; Poulter NR; Sever PS; Dahlof B; Wedel H; Beevers G; Caulfield M; Collins R; et alKjeldsen SE; Kristinsson A; McInnes GT; Mehlsen J; Nieminen M; O'Brien E. (1 Nov 2008). The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetes. JOURNAL OF HYPERTENSION. 26:2103-2111. Author weblink DOI.
  • Arshad S; Gupta AK; Poulter NR. (1 Oct 2008). Comparison of effectiveness and safety of fixed-dose combinations of antihypertensive agents with the free-drug combination of its components when given separately in hypertensive patients: a meta-analysis of 32 134 patients. JOURNAL OF HUMAN HYPERTENSION. 22:726-726. Author weblink.
  • Poulter NR. (1 Sep 2008). Selecting a fixed combination to improve morbidity/mortality: the weight of evidence with ASCOT. EUROPEAN HEART JOURNAL SUPPLEMENTS. 10:G21-G28. Author weblink DOI.
  • Sharp A; Tapp R; Francis DP; McG Thom SA; Hughes AD; Stanton AV; Zambanini A; Chaturvedi N; et alByrd S; Poulter NR; Sever PS; Mayet J. (16 Sep 2008). Ethnicity and left ventricular diastolic function in hypertension an ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial) substudy. J Am Coll Cardiol. 52:1015-1021. DOI.
  • Chapman N; Chang CL; Dahlof B; Sever PS; Wedel H; Poulter NR. (1 Jul 2008). Effect of doxazosin gastrointestinal therapeutic system as third-line antihypertensive therapy on blood pressure and lipids in the Anglo-Scandinavian Cardiac Outcomes Trial. CIRCULATION. 118:42-48. Author weblink DOI.
  • Sever PS; Poulter NR; Dahlof B; Wedel H; Beevers G; Caulfield M; Collins R; Kjeldsen SE; et alKristinsson A; McInnes G; Mehlsen J; Nieminen MS; O'Brien ET; Ostergren J. (1 Feb 2008). The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure. EUROPEAN HEART JOURNAL. 29:499-508. Author weblink DOI.
  • Gupta AK; Dahlof B; Dobson J; Sever PS; Wedel H; Poulter NR; Anglo-Scandinavian Cardiac Outcomes Trial Investigators. (May 2008). Determinants of new-onset diabetes among 19,257 hypertensive patients randomized in the Anglo-Scandinavian Cardiac Outcomes Trial--Blood Pressure Lowering Arm and the relative influence of antihypertensive medication. Diabetes Care. 31:982-988. DOI.
  • Patel A; ADVANCE Collaborative Group; MacMahon S; Chalmers J; Neal B; Woodward M; Billot L; Harrap S; et alPoulter N; Marre M; Cooper M; Glasziou P; Grobbee DE; Hamet P; Heller S; Liu LS; Mancia G; Mogensen CE; Pan CY; Rodgers A; Williams B. (8 Sep 2007). Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 370:829-840. DOI.
  • Lindgren P; Buxton M; Kahan T; Poulter NR; Dahlöf B; Sever PS; Wedel H; Jönsson B; et alASCOT trial investigators. (Feb 2008). Economic evaluation of ASCOT-BPLA: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen. Heart. 94:e4. DOI.
  • Gupta AK; Poulter NR; Dahlof B; Sever P; Wedel H. (1 Oct 2007). Role of metabolic syndrome, independent of its components, in prediction of cardiovascular outcomes in hypertensive patients in the ASCOT-BPLA. JOURNAL OF HUMAN HYPERTENSION. 21:836-837. Author weblink.
  • Chapman N; Dobson J; Wilson S; Dahlof B; Sever PS; Wedel H; Poulter NR. (1 Sep 2007). Spironolactone in resistant hypertension - Reply. HYPERTENSION. 50:E58-E58. Author weblink DOI.
  • Gupta AK; Poulter NR. (9 Jul 2007). Antihypertensive-associated incident diabetes: Controversy persists. ARCHIVES OF INTERNAL MEDICINE. 167:1433-1433. Author weblink DOI.
  • Gupta AK; Poulter NR. (9 Jul 2007). Antihypertensive-associated incident diabetes: controversy persists. Arch Intern Med. 167:1433. DOI.
  • Chapman N; Dobson J; Wilson S; Dahlöf B; Sever PS; Wedel H; Poulter NR; Anglo-Scandinavian Cardiac Outcomes Trial Investigators. (Apr 2007). Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension. 49:839-845. DOI.
  • Wilson SL; Poulter NR. (1 Jan 2007). Effects of non-steroidal anti-inflammatory drugs on blood pressure - Reply. JOURNAL OF HYPERTENSION. 25:248-249. Author weblink DOI.
  • Spence JD. (Jan 2007). Effects of non-steroidal anti-inflammatory drugs on blood pressure. J Hypertens. 25:248. DOI.
  • Wilson SL; Poulter NR. (Aug 2006). The effect of non-steroidal anti-inflammatory drugs and other commonly used non-narcotic analgesics on blood pressure level in adults. J Hypertens. 24:1457-1469. DOI.
  • Sever PS; Poulter NR. (13 Jun 2006). Blood pressure reduction is not the only determinant of outcome - Response to Elliott et al. CIRCULATION. 113:2773-2773. Author weblink.
  • Sever PS; Poulter NR; Elliott WJ; Jonsson MC; Black HR; Sever PS; Poulter NR; Elliott WJ; et alJonsson MC; Black HR. (13 Jun 2006). Blood pressure reduction is not the only determinant of outcome. Circulation. 113:2754-2772. DOI.
  • Sever PS; Poulter NR. (13 Jun 2006). Management of hypertension: is it the pressure or the drug? Blood pressure reduction is not the only determinant of outcome. CIRCULATION. 113:2754-2763. Author weblink DOI.
  • Primatesta P; Poulter NR. (Jun 2006). Improvement in hypertension management in England: results from the Health Survey for England 2003. J Hypertens. 24:1187-1192. DOI.
  • Primatesta P; Poulter NR. (Mar 2006). Levels of dyslipidaemia and improvement in its management in England: results from the Health Survey for England 2003. Clin Endocrinol (Oxf). 64:292-298. DOI.
  • Poulter NR; Sever PS; Dahlof B; Wedel H. (1 Oct 2005). Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes - Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA) - Response to Tseng. DIABETES CARE. 28:2595-2596. Author weblink.
  • Dahlöf B; Sever PS; Poulter NR; Wedel H; Beevers DG; Caulfield M; Collins R; Kjeldsen SE; et alKristinsson A; McInnes GT; Mehlsen J; Nieminen M; O'Brien E; Ostergren J; ASCOT Investigators. (10 Sep 2005). Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 366:895-906. DOI.
  • Poulter NR; Wedel H; Dahlöf B; Sever PS; Beevers DG; Caulfield M; Kjeldsen SE; Kristinsson A; et alMcInnes GT; Mehlsen J; Nieminen M; O'Brien E; Ostergren J; Pocock S; ASCOT Investigators. (10 Sep 2005). Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet. 366:907-913. DOI.
  • Sever PS; Poulter NR; Dahlöf B; Wedel H; Anglo-Scandinavian Cardiac Outcomes Trial Investigators. (5 Sep 2005). Different time course for prevention of coronary and stroke events by atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA). Am J Cardiol. 96:39F-44F. DOI.
  • Sever PS; Poulter NR; Dahlöf B; Wedel H; Collins R; Beevers G; Caulfield M; Kjeldsen SE; et alKristinsson A; McInnes GT; Mehlsen J; Nieminen M; O'Brien E; Ostergren J. (May 2005). Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA). Diabetes Care. 28:1151-1157.
  • Lindgren P; Buxton M; Kahan T; Poulter NR; Dahlöf B; Sever PS; Wedel H; Jönsson B; et alASCOT investigators. (Feb 2005). Cost-effectiveness of atorvastatin for the prevention of coronary and stroke events: an economic analysis of the Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA). Eur J Cardiovasc Prev Rehabil. 12:29-36.
  • Ruilope LM; Rosei EA; Bakris GL; Mancia G; Poulter NR; Taddei S; Unger T; Volpe M; et alWaeber B; Zannad F. (2005). Angiotensin receptor blockers: therapeutic targets and cardiovascular protection. Blood Press. 14:196-209. DOI.
  • Primatesta P; Falaschetti E; Poulter NR. (Jan 2005). Birth weight and blood pressure in childhood: results from the Health Survey for England. Hypertension. 45:75-79. DOI.
  • Primatesta P; Poulter NR. (Dec 2004). Lipid levels and the use of lipid-lowering agents in England and Scotland. Eur J Cardiovasc Prev Rehabil. 11:484-488.
  • Poulter NR. (27 Nov 2004). NICE and BHS guidelines on hypertension differ importantly. BRITISH MEDICAL JOURNAL. 329:1289-+. Author weblink DOI.
  • Poulter NR; BHS Executive Committees. (27 Nov 2004). NICE and BHS guidelines on hypertension differ importantly. BMJ. 329:1289. DOI.
  • Poulter NR. (Oct 2004). Measures of global risk: old versus new methods. Clin Exp Hypertens. 26:653-662.
  • Poulter NR. (Oct 2004). Modulating the design of clinical trials to address the question of mechanisms of disease. Clin Exp Hypertens. 26:727-730.
  • Primatesta P; Poulter NR. (Jun 2004). Hypertension management and control among English adults aged 65 years and older in 2000 and 2001. J Hypertens. 22:1093-1098.
  • Poulter NR. (1 May 2004). Announcement about ASCOT-LLA. LANCET. 363:1478-1478. Author weblink DOI.
  • Williams B; Poulter NR; Brown MJ; Davis M; McInnes GT; Potter JF; Sever PS; Thom SM; et alBHS guidelines working party, for the British Hypertension Society. (13 Mar 2004). British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ. 328:634-640. DOI.
  • Williams B; Poulter NR; Brown MJ; Davis M; McInnes GT; Potter JF; Sever PS; McG Thom S; et alBritish Hypertension Society. (Mar 2004). Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens. 18:139-185. DOI.
  • Sever PS; Dahlof B; Poulter NR; Wedel H; Beevers G; Caulfield M; Collins R; Kjeldsen SE; et alKristinsson A; McInnes GT; Mehlsen J; Nieminen M; O'Brien E; Ostergren J; ASCOT investigators. (Feb 2004). Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid lowering arm (ASCOT-LLA): A multicentre randomised controlled trial. DRUGS. 64:43-60.
  • Wolf-Maier K; Cooper RS; Kramer H; Banegas JR; Giampaoli S; Joffres MR; Poulter N. (2004). Hypertension treatment and control in five European Countries, Canada, and the United States. Hypertension. 43:10-17.
  • Mancia G; Rosei EA; Cifkova R; DeBacker G; Erdine S; Fagard R; Farsang C; Heagerty AM; et alKawecka-Jaszcs K; Kiowski W; Kjeldsen S; Luscher T; McInnes G; Mallion JM; Brien EO; Poulter NR; Priori SG; Rahn KH; Rodicio JL; Ruilope LM; Safar M; Staessen JA; van Zwieten P; Waeber B; Williams B; Zanchetti A; Zannad F. (1 Jun 2003). 2003 European society of hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. JOURNAL OF HYPERTENSION. 21:1011-1053. Author weblink DOI.
  • Sever PS; Dahlöf B; Poulter NR; Wedel H; Beevers G; Caulfield M; Collins R; Kjeldsen SE; et alKristinsson A; McInnes GT; Mehlsen J; Nieminen M; O'Brien E; Ostergren J; ASCOT investigators. (5 Apr 2003). Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 361:1149-1158. DOI.
  • Wilson S; Johnston A; Robson J; Poulter NR; Collier DJ; Feder GS; Caulfield MJ. (Apr 2003). Predicting coronary risk in the general population--is it necessary to measure high-density lipoprotein cholesterol?. J Cardiovasc Risk. 10:137-141. DOI.
  • Brown MJ; Cruickshank JK; Dominiczak AF; MacGregor GA; Poulter NR; Russell GI; Thom S; Williams B; et alExecutive Committee, British Hypertension Society. (Feb 2003). Better blood pressure control: how to combine drugs. J Hum Hypertens. 17:81-86. DOI.
  • Primatesta P; Falaschetti E; Poulter NR. (Feb 2003). Influence of hormone replacement therapy on C-reactive protein: population-based data. J Cardiovasc Risk. 10:57-60. DOI.
  • World Health Organization-International Society of Hypertension Writing Group. (2003). 2003 WHO-ISH statement on management of hypertension. J Hypertens. 21:1983-1992.
  • Wilson S; Johnston A; Robson J; Poulter N; et al. (2003). Comparison of methods to identify individuals at increased risk of coronary disease from the general population. BMJ. 236:1436-1438.
  • Poulter N. (2003). Global risk of cardiovascular disease. Heart. 89.
  • Wolf-Maier K; Cooper RS; Banegas JR; Giampaoli S; Hense H-W; Joffres M; Kastarinen M; Poulter N; et alet al. (2003). Hypertension prevalence and blood pressuer levels in 6 European countries, Canada and the United States. JAMA. 18:2363-2369.
  • Poulter NR. (2003). Prospects for hypertension in the next decade. Br J Cardiol. 10:418-420.
  • Donaghy M; Chang CL; Poulter N; European Collaborators of The World Health Organisation Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. (Dec 2002). Duration, frequency, recency, and type of migraine and the risk of ischaemic stroke in women of childbearing age. J Neurol Neurosurg Psychiatry. 73:747-750.
  • Wimalasundera RC; Larbalestier N; Smith JH; de Ruiter A; McG Thom SA; Hughes AD; Poulter N; Regan L; et alTaylor GP. (12 Oct 2002). Pre-eclampsia, antiretroviral therapy, and immune reconstitution. Lancet. 360:1152-1154.
  • Chang CL; Shipley MJ; Marmot MG; Poulter NR. (Aug 2002). Can cardiovascular risk factors explain the association between education and cardiovascular disease in young women?. J Clin Epidemiol. 55:749-755.
  • Chang CL; Marmot MG; Farley TM; Poulter NR. (Aug 2002). The influence of economic development on the association between education and the risk of acute myocardial infarction and stroke. J Clin Epidemiol. 55:741-747.
  • Ariff B; Stanton A; Barratt D; Augst A; Glor F; Poulter N; Sever P; Xu Y; et alHughes A; Thom SA. (Jun 2002). Comparison of the effects of antihypertensive treatment with angiotensin II blockade and beta-blockade on carotid wall structure and haemodynamics: protocol and baseline demographics. J Renin Angiotensin Aldosterone Syst. 3:116-122. DOI.
  • Poulter NR. (Feb 2002). Independent effects of smoking on risk of hypertension: small, if present. J Hypertens. 20:171-172.
  • Williams B; Poulter N. (2002). AASK commentary. Curr Concepts Hyper. 4:1-6.
  • Sever P; Poulter N. (2002). Hypertension trials - the current evidence base and forthcoming trials. Br J Cardiol. 9:640-644.
  • Poulter NR. (20 Dec 2001). High-density lipoprotein and coronary artery disease: The fibrate renaissance - Introduction. AMERICAN JOURNAL OF CARDIOLOGY. 88:1N-2N. Author weblink.
  • Poulter N; Williams B. (Nov 2001). Doxazosin for the management of hypertension: implications of the findings of the ALLHAT trial. Am J Hypertens. 14:1170-1172.
  • Stanton AV; Chapman JN; Mayet J; Sever PS; Poulter NR; Hughes AD; Thom SA. (Nov 2001). Effects of blood pressure lowering with amlodipine or lisinopril on vascular structure of the common carotid artery. Clin Sci (Lond). 101:455-464.
  • Poulter NR. (27 Oct 2001). Uses of error: Suppositions and surprises. LANCET. 358:1448-1448. Author weblink DOI.
  • Primatesta P; Brookes M; Poulter NR. (Oct 2001). Improved hypertension management and control: results from the health survey for England 1998. Hypertension. 38:827-832.
  • (Sep 2001). Study rationale and design of ADVANCE: action in diabetes and vascular disease--preterax and diamicron MR controlled evaluation. Diabetologia. 44:1118-1120.
  • Stanton A; Fitzgerald D; Hughes A; Mayet J; O'Brien E; Poulter NR; Sever PS; Shields D; et alThom S; Anglo-Scandinavian Cardiac Outcomes Trial. (Aug 2001). An intensive phenotyping study to enable the future examination of genetic influences on hypertension-associated cardiovascular disease. J Hum Hypertens. 15 Suppl 1:S13-S18.
  • Sever PS; Dahlof B; Poulter NR; Wedel H; Beevers G; Caulfield M; Collins R; Kjeldsen SE; et alMcInnes GT; Mehlsen J; Nieminen M; O'Brien E; Ostergren J. (1 Aug 2001). Anglo-Scandinavian Cardiac Outcomes Trial: a brief history, rationale and outline protocol. JOURNAL OF HUMAN HYPERTENSION. 15:S11-S12. Author weblink.
  • Chapman JN; Kirby P; Caulfield MC; Poulter NR; Anglo-Scandinavian Cardiac Outcomes Trial. (Aug 2001). Cardiovascular risk factors in a cohort of 30,000 high-risk men and women in the UK: cross-sectional, retrospective and prospective studies of screenees for the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). J Hum Hypertens. 15 Suppl 1:S23-S26.
  • Kirby PL; Caulfield MC; Collier DJ; Eldridge S; Griffiths CG; Hemingway H; Poulter NR; Feder GS; et alAnglo-Scandinavian Cardiac Outcomes Trial. (Aug 2001). Differential response to amlodipine and atenolol mono-therapy for hypertension by ethnic group. J Hum Hypertens. 15 Suppl 1:S61-S64.
  • Poulter NR; Caulfield M; Feder G. (1 Aug 2001). Ethnic variations in response to a statin (EVIREST). JOURNAL OF HUMAN HYPERTENSION. 15:S87-S89. Author weblink.
  • Wilson S; Collier D; Johnston A; Poulter N; Feder G; Robson J; Caulfield M; Anglo-Scandinavian Cardiac Outcomes Trial. (Aug 2001). Evaluation of cardiovascular risk equations using the ASCOT cohort. J Hum Hypertens. 15 Suppl 1:S31-S33.
  • Jönsson B; Buxton M; Hertzman P; Kahan T; Poulter N; Anglo-Scandinavian Cardiac Outcomes Trial, Health Economics Working Group. (Aug 2001). Health economics of prevention of coronary heart disease and vascular events: a cost-effectiveness analysis based on the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). J Hum Hypertens. 15 Suppl 1:S53-S56.
  • Thom S; Whitehouse A; Sever P; Poulter N; Anglo-Scandinavian Cardiac Outcomes Trial. (Aug 2001). Non-specific effects of inclusion in a clinical trial: information from ASCOT. J Hum Hypertens. 15 Suppl 1:S81-S82.
  • Jönsson B; Buxton M; Kahan T; Poulter NR; Svarvar P; Anglo-Scandinavian Cardiac Outcomes Trial, Health Economic Working Group. (Aug 2001). The effects of cardiac events on quality of life and indirect costs. J Hum Hypertens. 15 Suppl 1:S91-S93.
  • Poulter NR. (23 Jun 2001). Birthweights, maternal cardiovascular events, and Barker hypothesis. Lancet. 357:1990-1991. DOI.
  • Sever PS; Dahlöf B; Poulter NR; Wedel H; Beevers G; Caulfield M; Collins R; Kjeldsen SE; et alMcInnes GT; Mehlsen J; Nieminen M; O'Brien E; Ostergren J. (Jun 2001). Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. ASCOT investigators. J Hypertens. 19:1139-1147.
  • Sever PS; Dahlof B; Poulter NR; Wedel H; Beevers G; Caulfield M; Collins R; Kjeldsen SE; et alMcInnes GT; Mehlsen J; Nieminen M; O'Brien E; Ostergren J. (1 Jun 2001). Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian cardiac outcomes trial. JOURNAL OF HYPERTENSION. 19:1139-1147. Author weblink DOI.
  • Chapman N; Mayet J; Ozkor M; Lampe FC; Thom SA; Poulter NR. (May 2001). QT intervals and QT dispersion as measures of left ventricular hypertrophy in an unselected hypertensive population. Am J Hypertens. 14:455-462.
  • Primatesta P; Poulter NR. (3 Mar 2001). Lipid concentrations and the use of lipid lowering drugs: evidence from a national cross sectional survey (vol 321, pg 1322, 2000). BRITISH MEDICAL JOURNAL. 322:525-525. Author weblink.
  • Primatesta P; Falaschetti E; Gupta S; Marmot MG; Poulter NR. (Feb 2001). Association between smoking and blood pressure: evidence from the health survey for England. Hypertension. 37:187-193.
  • Wilson SL; Poulter NR. (2001). Cardiovascular risk: its assessment in clinical practice. Br J Biomed Sci. 58:248-251.
  • Poulter NR. (2001). Oestrogen and protection against cardiovascular disease: potential versus reality. Br J Cardiol. 8:383-390.
  • Poulter NR. (2001). Oestrogen and protection against cardiovascular disease: potential versus reality. Br J Cardiol. 8:383-390.
  • Primatesta P; Poulter NR. (25 Nov 2000). Lipid concentrations and the use of lipid lowering drugs: evidence from a national cross sectional survey. BMJ. 321:1322-1325.
  • Mayet J; Ariff B; Wasan B; Chapman N; Shahi M; Poulter NR; Sever PS; Foale RA; et alThom SA. (Nov 2000). Improvement in midwall myocardial shortening with regression of left ventricular hypertrophy. Hypertension. 36:755-759.
  • McInnes GT; Mancia G; Sever PS; Poulter NR. (Oct 2000). Applying evidence-based medicine to current practice: a round table panel discussion. J HUM HYPERTENS. 14:S17-S22.
  • Poulter NR. (Oct 2000). Benefits and pitfalls of cardiovascular risk assessment. J Hum Hypertens. 14 Suppl 2:S11-S16.
  • Sever PS; Poulter NR. (Oct 2000). Hypertension drug trials: past, present, and future. J Hum Hypertens. 14:729-738.
  • Poulter NR. (17 Jun 2000). Risk of fatal pulmonary embolism with oral contraceptives. LANCET. 355:2088-2088. Author weblink DOI.
  • Guzzetti S; Mayet J; Shahi M; Mezzetti S; Foale RA; Sever PS; Poulter NR; Porta A; et alMalliani A; Thom SA. (May 2000). Absence of sympathetic overactivity in Afro-Caribbean hypertensive subjects studied by heart rate variability. J Hum Hypertens. 14:337-342.
  • Ramsay LE; Williams B; Potter JF; Johnston GD; MacGregor GA; Poston L; Poulter NR; Russell G. (26 Feb 2000). Management of hypertension - Reply. BRITISH MEDICAL JOURNAL. 320:579-580. Author weblink.
  • Primatesta P; Bost L; Poulter NR. (Feb 2000). Blood pressure levels and hypertension status among ethnic groups in England. J Hum Hypertens. 14:143-148.
  • Chapman JN; French AT; Poulter NR; Sever PS. (Feb 2000). Page's syndrome: a case of pseudophaeochromocytoma. J Hum Hypertens. 14:149-150.
  • Poulter NR; Chang CL; MacGregor AJ; Snieder H; Spector TD. (20 Nov 1999). Association between birth weight and adult blood pressure in twins: historical cohort study. BMJ. 319:1330-1333.
  • Poulter NR; Chang CL; Farley TM; Meirik O. (6 Nov 1999). Risk of cardiovascular diseases associated with oral progestagen preparations with therapeutic indications. Lancet. 354:1610.
  • Ramsay LE; Williams B; Johnston GD; MacGregor GA; Poston L; Potter JF; Poulter NR; Russell G. (4 Sep 1999). British Hypertension Society guidelines for hypertension management 1999: summary. BMJ. 319:630-635.
  • Ramsay LE; Williams B; Johnston GD; MacGregor GA; Poston L; Potter JF; Poulter NR; Russell G. (1 Sep 1999). Guidelines for management of hypertension: report of the third working party of the British Hypertension Society. JOURNAL OF HUMAN HYPERTENSION. 13:569-592. Author weblink DOI.
  • Poulter NR; Chang CL; Farley TMM; Marmot MG; Meirik O. (24 Jul 1999). Effect on stroke of different progestagens in low oestrogen dose oral contraceptives. LANCET. 354:301-302. Author weblink DOI.
  • Poulter NR; Chang CL; Farley TM; Marmot MG; Meirik O. (24 Jul 1999). Effect on stroke of different progestagens in low oestrogen dose oral contraceptives. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet. 354:301-302.
  • Chapman JN; Mayet J; Chang CL; Foale RA; Thom SA; Poulter NR. (May 1999). Ethnic differences in the identification of left ventricular hypertrophy in the hypertensive patient. Am J Hypertens. 12:437-442.
  • Poulter NR. (1 May 1999). Medical education - communicating best practice. ATHEROSCLEROSIS. 143:S13-S16. Author weblink DOI.
  • Donaghy M; Chang CL; Poulter NR. (1 May 1999). Migraine, oral contraception and stroke in young women. CEPHALALGIA. 19:308-308. Author weblink.
  • Mayet J; Kanagaratnam P; Shahi M; Senior R; Doherty M; Poulter NR; Sever PS; Handler CE; et alThom SA; Foale RA. (Apr 1999). QT dispersion in athletic left ventricular hypertrophy. Am Heart J. 137:678-681.
  • Powell JT; Franks PJ; Poulter NR. (Feb 1999). Does nibbling or grazing protect the peripheral arteries from atherosclerosis?. J Cardiovasc Risk. 6:19-22.
  • Chang CL; Donaghy M; Poulter N. (2 Jan 1999). Migraine and stroke in young women: case-control study. The World Health Organisation Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. BMJ. 318:13-18.
  • Chang CL; Donaghy M; Poulter NR. (1 Jan 1999). Stroke in young women: The influence of migraine and oral contraceptives. STROKE. 30:251-251. Author weblink.
  • Colhoun HM; Dong W; Barakat MT; Mather HM; Poulter NR. (Jan 1999). The scope for cardiovascular disease risk factor intervention among people with diabetes mellitus in England: a population-based analysis from the Health Surveys for England 1991-94. Diabet Med. 16:35-40.
  • Farley TM; Meirik O; Chang CL; Poulter NR. (Dec 1998). Combined oral contraceptives, smoking, and cardiovascular risk. J Epidemiol Community Health. 52:775-785.
  • Poulter NR. (12 Nov 1998). Calcium antagonists and the diabetic patient: a response to recent controversies. Am J Cardiol. 82:40R-41R.
  • Poulter NR. (19 Sep 1998). Dietary sodium intake and mortality: NHANES. LANCET. 352:987-988. Author weblink DOI.
  • Poulter NR. (19 Sep 1998). Dietary sodium intake and mortality: NHANES. The Faculty 31st International Society and Federation of Cardiology 10-day Teaching Seminar in Cardiovascular Disease, Epidemiology and Prevention. National Health and Nutrition Examination Survey. Lancet. 352:987-988.
  • Poulter NR. (13 Jun 1998). Calcium channel blockers and cardiovascular risk in diabetes. Lancet. 351:1809-1810.
  • Dong W; Bost L; Primatesta P; Poulter NR. (1 Jun 1998). Blood pressure and serum antioxidant levels: Evidence from the Scottish Health Survey (SHS) 1995. JOURNAL OF HYPERTENSION. 16:S253-S253. Author weblink.
  • Colhoun HM; Dong W; Poulter NR. (Jun 1998). Blood pressure screening, management and control in England: results from the health survey for England 1994. J Hypertens. 16:747-752.
  • Colhoun HM; Dong W; Poulter NR. (1 Jun 1998). Hormone replacement therapy use and blood pressure: Results from the health surveys for England 1993 and 1994. JOURNAL OF HYPERTENSION. 16:S5-S5. Author weblink.
  • Chang CL; Donaghy M; Poulter NR. (1 Jun 1998). Interaction of migraine and hypertension on stroke risk. JOURNAL OF HYPERTENSION. 16:S203-S203. Author weblink.
  • Poulter NR; Chang CL; Farley TMM; Meirik O. (1 Jun 1998). Progestogen-only contraceptives, hypertension history and stroke risk. JOURNAL OF HYPERTENSION. 16:S198-S198. Author weblink.
  • Colhoun H; Hemingway H; Poulter NR. (1 Jun 1998). Socio-economic status and blood pressure; overview of published data: 1966-1996. JOURNAL OF HYPERTENSION. 16:S252-S252. Author weblink.
  • Mayet J; Chapman N; Li CK; Shahi M; Poulter NR; Sever PS; Foale RA; Thom SA. (May 1998). Ethnic differences in the hypertensive heart and 24-hour blood pressure profile. Hypertension. 31:1190-1194.
  • Dong W; Bost LD; Primatesta P; Calhoun HM; Poulter NR; Marmot MG. (3 Mar 1998). Ascorbic acid, fibrinogen and cardiovascular disease-links observed in the 1995 Scottish health survey. CIRCULATION. 97:814-814. Author weblink.
  • Poulter NR; Alberti KGMM; Beevers DG; Betteridge DJ; Campbell RWF. (7 Feb 1998). Drug therapy for coronary heart disease: the Sheffield table - Reply. LANCET. 351:443-444. Author weblink DOI.
  • Colhoun HM; Hemingway H; Poulter NR. (Feb 1998). Socio-economic status and blood pressure: an overview analysis. J Hum Hypertens. 12:91-110.
  • Farley TMM; Meirik O; Marmot MG; Chang CL; Poulter NR. (1 Jan 1998). Oral contraceptives and risk of venous thromboembolism: Impact of duration of use. CONTRACEPTION. 57:61-64. Author weblink.
  • Farley TM; Meirik O; Marmot MG; Chang CL; Poulter NR. (Jan 1998). Oral contraceptives and risk of venous thromboembolism: impact of duration of use. Contraception. 57:61-65.
  • Poulter NR; Alberti KG; Beevers DG; Betteridge DJ; Campbell RW. (20 Dec 1997). Drug therapy for coronary heart disease: the Sheffield table. Lancet. 350:1852-1853.
  • Dong W; Colhoun HM; Poulter NR. (Oct 1997). Blood pressure in women using oral contraceptives: results from the Health Survey for England 1994. J Hypertens. 15:1063-1068.
  • Chang CL; Farley TM; Marmot M; Poulter NR. (1 Oct 1997). The evaluation of agreement on continuous variables by the intraclass correlation coefficient - Reply. JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH. 51:580-581. Author weblink.
  • Mayet J; Shahi M; Poulter NR; Sever PS; Foale RA; Thom SA. (Sep 1997). Left ventricular geometry in presenting untreated hypertension. J Hum Hypertens. 11:593-594.
  • Mayet J; O'Kane KP; Elton R; Johnstone HA; Shahi M; Ozkor MA; Stanton AV; Poulter NR; et alSever PS; Foale RA; Webb DJ; Thom SA. (Sep 1997). Left ventricular hypertrophy, blood pressure and ACE genotype in untreated hypertension. J Hum Hypertens. 11:595-597.
  • Mayet J; Chapman N; Shahi M; Poulter NR; Cunningham DA; Dave S; Kooner J; Sever PS; et alFoale RA; Thom SA. (Jun 1997). The effects on cardiac arrhythmias of antihypertensive therapy causing regression of left ventricular hypertrophy. Am J Hypertens. 10:611-618.
  • Poulter NR; Chang CL; Farley TMM; Kelaghan J; Meirlk O; Marmot MG; DebertRibeiro M; Medina E; et alArtigas J; He S; Zhong YH; Zhang DW; Zhao WJ; Rojas O; Heinemann L; Donnan S; Ho S; Bartfai G; Kisjanto J; Wilks R; Agwanda R; Ruiz R; KozuhNovak M; Dusitsin N; Virutamasen P; Phanthumchinda K; Koetsawang S; PiyaAnant M; Vessey M; Demirovic J; Belkic K; Mwandila WS; Mutale CM; Matenga J; Wilson A; Vessey MP; Petitti D; Perlman J; Kelaghan J; Holck S; Lawley S; Smith S; Shipley M; Olsen J; Thorogood M. (26 Apr 1997). Acute myocardial infarction and combined oral contraceptives: Results of an international multicentre case-control study. LANCET. 349:1202-1209. Author weblink.
  • Poulter NR; Chang CL; Marmot M; Farley TM; Meirik O. (8 Mar 1997). Third-generation oral contraceptives and venous thrombosis. Lancet. 349:732.
  • Powell JT; Edwards RJ; Worrell PC; Franks PJ; Greenhalgh RM; Poulter NR. (28 Feb 1997). Risk factors associated with the development of peripheral arterial disease in smokers: a case-control study. Atherosclerosis. 129:41-48.
  • Poulter NR; Chang CL; Farley TM; Marmot MG. (Dec 1996). Reliability of data from proxy respondents in an international case-control study of cardiovascular disease and oral contraceptives. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. J Epidemiol Community Health. 50:674-680.
  • Poulter NR; Chang CL; Farley TMM; Marmot MG. (1 Dec 1996). Reliability of data from proxy respondents in an international case-control study of cardiovascular disease and oral contraceptives. JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH. 50:674-680. Author weblink DOI.
  • Mayet J; Shahi M; McGrath K; Poulter NR; Sever PS; Foale RA; Thom SA. (Nov 1996). Left ventricular hypertrophy and QT dispersion in hypertension. Hypertension. 28:791-796.
  • Farley TMM; Meirik O; Poulter NR; Chang CL; Marmot MG. (1 Sep 1996). Oral contraceptives and thrombotic diseases: Impact of new epidemiological studies. CONTRACEPTION. 54:193-195. Author weblink DOI.
  • Farley TM; Meirik O; Poulter NR; Chang CL; Marmot MG. (Sep 1996). Oral contraceptives and thrombotic diseases: impact of new epidemiological studies. Contraception. 54:193-198.
  • Poulter NR; Chang CL; Farley TMM; Meirik O; Marmot MG. (24 Aug 1996). Haemorrhagic stroke, overall stroke risk, and combined oral contraceptives: Results of an international, multicentre, case-control study. LANCET. 348:505-510. Author weblink.
  • Poulter NR; Chang CL; Farley TMM; Meirik O; Marmot MG; DebertRibeiro M; Medina E; Artigas J; et alShen H; Zhong YH; Zhang DW; Zhao WJ; Rojas O; Vessey M; Heinemann L; Donnan S; Ho S; Bartfai G; Kisjanto J; Wilks R; Agwanda R; Ruiz R; KozuhNovak M; Dusitsin N; Virutamasen P; Phanthumcinda K; Koetsawang S; PiyaAnant M; Demirovic J; Belkic K; Mwandila WS; Mutale CM; Matenga J; Wilson A; Petitti D; Perlman J; Keleghan J; Lawley S; Smith S; Shipley M; Olsen J; Thorogood M. (24 Aug 1996). Ischaemic stroke and combined oral contraceptives: Results of an international, multicentre, case-control study. LANCET. 348:498-505. Author weblink.
  • Poulter NR; Zographos D; Mattin R; Sever PS; Thom SM. (Jul 1996). Concomitant risk factors in hypertensives: a survey of risk factors for cardiovascular disease amongst hypertensives in English general practices. Blood Press. 5:209-215.
  • Poulter NR. (May 1996). Managing the diabetic hypertensive patient. J Diabetes Complications. 10:141-143. DOI.
  • Smith I; Franks PJ; Greenhalgh RM; Poulter NR; Powell JT. (May 1996). The influence of smoking cessation and hypertriglyceridaemia on the progression of peripheral arterial disease and the onset of critical ischaemia. Eur J Vasc Endovasc Surg. 11:402-408.
  • Poulter NR; Farley TMM; Chang CL; Marmot MG; Meirik O. (24 Feb 1996). Safety of combined oral contraceptive pills - Reply. LANCET. 347:547-547. Author weblink.
  • FARLEY TMM; MEIRIK O; CHANG CL; MARMOT MG; POULTER NR. (16 Dec 1995). EFFECT OF DIFFERENT PROGESTAGENS IN LOW ESTROGEN ORAL-CONTRACEPTIVES ON VENOUS THROMBOEMBOLIC DISEASE. LANCET. 346:1582-1588. Author weblink.
  • POULTER NR; CHANG CL; FARLEY TMM; MEIRIK O; MARMOT MG; DEBERTRIBEIRO M; MEDINA E; ARTIGAS J; et alHE S; ZHONG YH; ZHANG DW; ZHAO WJ; ROJAS O; VESSEY MP; HEINEMANN L; DONNAN S; HO S; BARTFAI G; KISJANTO J; WILKS R; AGWANDA R; RUIZ R; KOZUHNOVAK M; DUSITSIN N; VIRUTAMASEN P; PHANTHUMCHINDA K; KOETSAWANG S; PIYAANANT M; DEMIROVIC J; BELKIC K; MWANDILA WS; MUTALE CM; MATENGA J; WILSON A; PETITTI D; HOLCK S; LAWLEY S; SMITH S; SHIPLEY M; OLSEN J; THOROGOOD M; KELAGHAN J. (16 Dec 1995). VENOUS THROMBOEMBOLIC DISEASE AND COMBINED ORAL-CONTRACEPTIVES - RESULTS OF INTERNATIONAL MULTICENTER CASE-CONTROL STUDY. LANCET. 346:1575-1582. Author weblink.
  • Mayet J; Stanton AV; Sinclair AM; MacKay J; Shahi M; Foale RA; Nicolaides A; Poulter NR; et alSever PS; Thom SA. (Jul 1995). The effects of antihypertensive therapy on carotid vascular structure in man. Cardiovasc Res. 30:147-152.
  • Mayet J; Shahi M; Poulter NR; Sever PS; Foale RA; Thom SA. (30 Jun 1995). Left ventricular diastolic function in hypertension: a 4 year follow-up study. Int J Cardiol. 50:181-188.
  • Mayet J; Shahi M; Hughes AD; Stanton AV; Poulter NR; Sever PS; Foale RA; Thom SA. (Jun 1995). Left ventricular structure and function in previously untreated hypertensive patients: the importance of blood pressure, the nocturnal blood pressure dip and heart rate. J Cardiovasc Risk. 2:255-261.
  • Mayet J; Shahi M; Poulter NR; Sever PS; Thom SA; Foale RA. (Feb 1995). Ventricular arrhythmias in hypertension: in which patients do they occur?. J Hypertens. 13:269-276.
  • Poulter NR. (Sep 1994). Beyond blood pressure. J Hum Hypertens. 8 Suppl 1:S3-S8.
  • Staessen JA; Poulter NR; Fletcher AE; Markowe HL; Marmot MG; Shipley MJ; Bulpitt CJ. (Jun 1994). Psycho-emotional stress and salt intake may interact to raise blood pressure. J Cardiovasc Risk. 1:45-51.
  • Poulter NR. (May 1994). Risk factors for cardiovascular disease: 'clustering' in the older hypertensive man. Br J Clin Pract Suppl. 74:4-7.
  • Mayet J; Shahi M; Foale RA; Poulter NR; Sever PS; McG Thom SA. (16 Apr 1994). Racial differences in cardiac structure and function in essential hypertension. BMJ. 308:1011-1014.
  • Poulter NR; Sanderson JE; Thompson AV; Sever PS; Chang CL. (6 Mar 1993). Comparison of nifedipine and propranolol as second line agent for hypertension in black Kenyans. BMJ. 306:621-622.
  • Marmot MG; Poulter NR. (8 Feb 1992). Primary prevention of stroke. Lancet. 339:344-347.
  • Poulter NR. (Dec 1991). From stepped care to tailored therapy. J Hum Hypertens. 5 Suppl 2:17-22.
  • Poulter NR. (1991). Treatment of hypertension: a clinical epidemiologist's view. J Cardiovasc Pharmacol. 18 Suppl 2:S35-S38.
  • Poulter NR. (Oct 1990). Major risk factors for coronary heart disease in hypertension: implications for management. J Hum Hypertens. 4 Suppl 3:3-6.
  • POULTER NR. (1 Oct 1990). MAJOR RISK-FACTORS FOR CORONARY HEART-DISEASE IN HYPERTENSION - IMPLICATIONS FOR MANAGEMENT. JOURNAL OF HUMAN HYPERTENSION. 4:3-6. Author weblink.
  • Poulter NR; Khaw KT; Hopwood BE; Mugambi M; Peart WS; Rose G; Sever PS. (14 Apr 1990). The Kenyan Luo migration study: observations on the initiation of a rise in blood pressure. BMJ. 300:967-972.
  • Sever PS; Poulter NR; Bulpitt CS. (Mar 1989). Double-blind crossover versus parallel groups in hypertension. Am Heart J. 117:735-739.
  • Sever PS; Poulter NR. (Feb 1989). A hypothesis for the pathogenesis of essential hypertension: the initiating factors. J Hypertens Suppl. 7:S9-12.
  • Poulter NR; Shipley MJ; Bulpitt CJ; Markowe HJ; Marmot MG. (Dec 1988). Pulse rate and twenty-four hour urinary sodium content interact to determine blood pressure levels of male London civil servants. J Hypertens Suppl. 6:S611-S613.
  • POULTER NR; KHAW KT; SEVER PS. (1 Jul 1988). HIGHER BLOOD PRESSURES OF URBAN MIGRANTS FROM AN AFRICAN LOW BLOOD PRESSURE POPULATION ARE NOT DUE TO SELECTIVE MIGRATION. AMERICAN JOURNAL OF HYPERTENSION. 1:S143-S145. Author weblink.
  • Poulter NR; Khaw KT; Sever PS. (Jul 1988). Higher blood pressures of urban migrants from an African low-blood pressure population are not due to selective migration. Am J Hypertens. 1:143S-145S.
  • Sever PS; Poulter NR. (Dec 1987). Calcium antagonists and diuretics as combined therapy. J Hypertens Suppl. 5:S123-S126.
  • Thompson AV; Poulter NR. (Jan 1987). Case report of an atypical presentation of falciparum malaria. East Afr Med J. 64:88-89.
  • Poulter NR; Sever PS. (Dec 1986). Moderate potassium supplementation: ineffective in black normotensives. East Afr Med J. 63:798-802.
  • POULTER NR; LURY JD; THOMPSON AV. (1 Jun 1986). BLOOD PRESSURES HIGHER IN THE HOME THAN IN THE CLINIC IN RURAL KENYA. JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH. 40:186-187. Author weblink DOI.
  • Poulter NR; Sanderson JE. (Jun 1986). Reserpine versus beta-blocker as an additive to a diuretic in the treatment of Kenyan hypertensives. East Afr Med J. 63:412-416.
  • POULTER NR; KHAW K; HOPWOOD BE; MUGAMBI M; PEART WS; SEVER PS. (1 Dec 1985). DETERMINANTS OF BLOOD-PRESSURE CHANGES DUE TO URBANIZATION - A LONGITUDINAL-STUDY. JOURNAL OF HYPERTENSION. 3:S375-S377. Author weblink.
  • POULTER NR; KHAW KT; MUGAMBI M; PEART WS; ROSE G; SEVER P. (1 Jan 1985). BLOOD-PRESSURE PATTERNS IN RELATION TO AGE, WEIGHT AND URINARY ELECTROLYTES IN 3 KENYAN COMMUNITIES. TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE. 79:389-392. Author weblink DOI.
  • POULTER NR; KHAW KT; MUGAMBI M; PEART WS; SEVER PS. (1 Jan 1985). MIGRATION-INDUCED CHANGES IN BLOOD-PRESSURE - A CONTROLLED LONGITUDINAL-STUDY. CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY. 12:211-216. Author weblink DOI.
  • SPENCER HC; POULTER NR; LURY JD; POULTER CJ. (1 Jan 1982). CHLOROQUINE-ASSOCIATED PRURITUS IN A EUROPEAN. BRITISH MEDICAL JOURNAL. 285:1703-1704. Author weblink.

Books

  • Poulter NR. Combination Therapy in Hypertension. Nova Professional Media, Salop (2010).
  • Poulter N; Kirby M. Hypertension: A guide to assessment and management. (2002).
  • Poulter N; Thom S; Kirby M. Shared care for hypertension. (2001).

Conferences

  • Zoungas S; Ninomiya T; Patel A; Perkovic V; Woodward M; Grobbee D; Harrap S; Macmahon S; et alMancia G; Marre M; Mogensen C; Neal B; Poulter N; Williams B; Chalmers J. THE EFFECTS OF A FIXED COMBINATION OF PERINDOPRIL AND INDAPAMIDE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS ACCORDING TO BASELINE CARDIOVASCULAR RISK IN THE ADVANCE TRIAL. 19th European Meeting on Hypertension, 12 Jun 2009 - 16 Jun 2009. 27:S314-S314. LIPPINCOTT WILLIAMS & WILKINS (1 Jun 2009). Author weblink.
  • Gupta AK; et al. The relationship between statin therapy and progression of renal damage among 10,305 hypertensive patients randomised in the ASCOT-lipid-lowering arm (LLA). European Atherosclerosis Society Congress, 26 Jun 2011 - 29 Jun 2011. (Jun 2011).
  • Poulter N. Decreasing coronary events: Recent trial evidence. 21sth Scientific Meeting of the International-Society-of-Hypertension/5th Asian-Pacific Congress of Hypertension/29th Annual Scientific Meeting of the Japanese-Society-of-Hypertension, 15 Oct 2006 - 19 Oct 2006. 24:417-417. LIPPINCOTT WILLIAMS & WILKINS (1 Dec 2006). Author weblink.
  • Berglund T; Dahlof B; Sever P; Poulter N; Wedel H. THE PREDICTIVE VALUE OF REGRESSION OF ELECTROCARDIOGRAPHIC LEFT VENTRICULAR HYPERTROPHY DURING ANTI HYPERTENSIVE TREATMENT IN THE ASCOT STUDY. 19th European Meeting on Hypertension, 12 Jun 2009 - 16 Jun 2009. 27:S180-S180. LIPPINCOTT WILLIAMS & WILKINS (1 Jun 2009). Author weblink.
  • Chalmers J; Marre M; de Galan B; Zoungas S; Hamet P; Neal B; Poulter N; Patel A. The efficacy of lowering HbA(1c) with a gliclazide modified release-based intensive glucose lowering regimen in the ADVANCE trial. 45th Annual Meeting of the European-Association-for-the-Study-of-Diabetes, 29 Sep 2009 - 2 Oct 2009. 52:S354-S354. SPRINGER (1 Sep 2009). Author weblink.
  • Koren M; Lindgren P; Buxton M; Kahan T; Poulter N; Dahlof B; Sever P; Wedel H; et alTang SS; Jonsson B. Cost-effectiveness of multi-drug regimen of amlodipine plus atorvastatin based on the anglo-scandinavian cardiac outcomes trial (ASCOT): An economic sub-analysis. 8th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke, 9 May 2007 - 11 May 2007. 115:E568-E568. LIPPINCOTT WILLIAMS & WILKINS (29 May 2007). Author weblink.
  • Poulter N. The weight of evidence with ASCOT. 18th Scientific Meeting of the European-Society-of-Hypertension/22nd Scientific Meeting of the International-Society-of-Hypertension, 14 Jun 2008 - 19 Jun 2008. 26:S531-S531. LIPPINCOTT WILLIAMS & WILKINS (1 Jun 2008). Author weblink.
  • Ostergren J; Sever P; Poulter N; Dahlof B; Wedel H; Beevers G; Caulfield M; Collins R; et alKjeldsen S; Kristinsson A; McInnes G; Mehlsen J; Nieminen M; OBrien E. The Anglo-Scandinavian Cardiac Outcomes Trial: Blood pressure-lowering limb (ASCOT-BPLA): effects in patients with type 2 diabetes. 42nd Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD), 14 Sep 2006 - 17 Sep 2006. 49:136-137. SPRINGER (1 Sep 2006). Author weblink.
  • Berglund T; Dahloef B; Sever P; Poulter N; Wedel H. Differential regression of electrocardiographic left ventricular hypertrophy by amlodipine versus atenolol in the ASCOT-trial. 18th Scientific Meeting of the European-Society-of-Hypertension/22nd Scientific Meeting of the International-Society-of-Hypertension, 14 Jun 2008 - 19 Jun 2008. 26:S254-S254. LIPPINCOTT WILLIAMS & WILKINS (1 Jun 2008). Author weblink.
  • Poulter N. Past, present and future clinical trials of cardiovascular risk reduction - The hyperlipidemia perspective. 13th International Symposium on Atherosclerosis, 28 Sep 2003 - 2 Oct 2003. 4:2-2. ELSEVIER SCI IRELAND LTD (1 Sep 2003). Author weblink DOI.
  • Donaghy M; Chang CL; Poulter N. Duration, frequency, recency and type of migraine and the risk of ischaemic stroke in women of childbearing age. 11th Congress of the International-Headache-Society, 12 Sep 2003 - 16 Sep 2003. 23:570-570. BLACKWELL PUBLISHING LTD (1 Sep 2003). Author weblink.
  • Sever P; Dahlof B; Poulter N; Wedel H. Cardiovascular event reduction in the anglo-scandinavian cardiac outcomes trial (ASCOT): Combined benefits of blood pressure reduction, lipid-lowering and treatment with a "newer" compared with an "older" antihypertensive treatment regimen. 21sth Scientific Meeting of the International-Society-of-Hypertension/5th Asian-Pacific Congress of Hypertension/29th Annual Scientific Meeting of the Japanese-Society-of-Hypertension, 15 Oct 2006 - 19 Oct 2006. 24:30-30. LIPPINCOTT WILLIAMS & WILKINS (1 Dec 2006). Author weblink.
  • Sever P; Dahlof B; Poulter N; Wedel H. Continued benefit on cardiovascular outcomes in the anglo- Scandinavian cardiac outcomes trial (ASCOT) two years after closure of the lipid-lowering arm (LLA). 16th European Meeting on Hypertension, 12 Jun 2006 - 15 Jun 2006. 24:S3-S3. LIPPINCOTT WILLIAMS & WILKINS (1 Jun 2006). Author weblink.
  • Sever P; Poulter N; Dahlof B; Wedel H. The magnitude of cardiovascular benefits from blood pressure lowering and lipid-lowering: Insights from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). 18th Scientific Meeting of the European-Society-of-Hypertension/22nd Scientific Meeting of the International-Society-of-Hypertension, 14 Jun 2008 - 19 Jun 2008. 26:S27-S27. LIPPINCOTT WILLIAMS & WILKINS (1 Jun 2008). Author weblink.
  • Wilson S; Johnston A; Robson J; Poulter N; Collier D; Feder G; Caulfield M. Should we measure high density lipoprotein cholesterol in people with hypertension?. 19th Meeting of the International-Society-for-Hypertension/12th European-Society-of-Hypertension Meeting, 23 Jun 2002 - 27 Jun 2002. 20:S150-S150. LIPPINCOTT WILLIAMS & WILKINS (1 Jun 2002). Author weblink.
  • Ho E; Rooney C; Harhen B; Sever P; Poulter N; Hughes A; Thom S; O'Brien E; et alFitzgerald D; Stanton A. Atherosclerosis and oxidative stress contribute to aspirin nonresponse in hypertensive subjects. 77th Scientific Meeting of the American-Heart-Association, 7 Nov 2004 - 10 Nov 2004. 110:608-608. LIPPINCOTT WILLIAMS & WILKINS (26 Oct 2004). Author weblink.
  • Tapp R; Sharp A; Stanton A; O'Brien E; Chaturvedi N; Sever P; Poulter N; Hughes A; et alThom S; Mayet J. Left ventricular diastolic function assessed by tissue Doppler echocardiography is impaired by beta-blocker plus diuretic-based therapy compared with calcium, antagonist plus Ace inhibitor-based therapy: An ASCOT substudy. 80th Annual Scientific Session of the American-Heart-Association, 4 Nov 2007 - 7 Nov 2007. 116:609-609. LIPPINCOTT WILLIAMS & WILKINS (16 Oct 2007). Author weblink.
  • Kengne A-P; Czernichow S; Huxley R; Grobbee D; Woodward M; Neal B; Zoungas S; Cooper M; et alGlasziou P; Hamet P; Harrap SB; Mancia G; Poulter N; Williams B; Chalmers J. Blood Pressure Variables and Cardiovascular Risk New Findings From ADVANCE. 7th International Workshop on Structure and Function of the Vascular System, 12 Mar 2009 - 14 Mar 2009. 54:399-404. LIPPINCOTT WILLIAMS & WILKINS (1 Aug 2009). Author weblink DOI.
  • Ariff B; O'Neill A; Stanton A; Zambanini A; Vamadeva S; Poulter N; Sever P; Xu Y; et alHughes A; Thom S. Candesartan cilexetil & atenolol have different effects on common carotid artery remodelling in hypertension. 13th European Meeting on Hypertension, 13 Jun 2003 - 17 Jun 2003. 21:S153-S154. LIPPINCOTT WILLIAMS & WILKINS (1 Jun 2003). Author weblink.
  • Poulter N; Sever PS. Do statins lower blood pressure? Evidence from the anglo-scandinavian cardiac outcomes trial-lipid-lowering arm (ASCOT-LLA). 77th Scientific Meeting of the American-Heart-Association, 7 Nov 2004 - 10 Nov 2004. 110:402-402. LIPPINCOTT WILLIAMS & WILKINS (26 Oct 2004). Author weblink.
  • Sharp AS; Zambanini A; Hughes AD; Byrd S; Shields D; Fitzgerald D; Lyons S; O'Brien E; et alStanton A; Poulter N; Sever PS; Thom SAG; Mayet J. Atorvastatin does not reduce LV mass or affect diastolic function after one year of treatment. Meeting of the British Society of Echocardiography. 89:41-42. (Nov 2003).
  • Hughes A; Manisty C; Zambanini A; Mayet J; Poulter N; Sever P; Parker K; Thom S. Lower augmentation index and wave reflection in hypertensive subjects treated with atorvastatin; An ASCOT-LLA substudy. 80th Annual Scientific Session of the American-Heart-Association, 4 Nov 2007 - 7 Nov 2007. 116:609-609. LIPPINCOTT WILLIAMS & WILKINS (16 Oct 2007). Author weblink.
  • Mansity C; Zambanini A; Poulter N; Sever P; Parker K; Thom S; Hughes A. Atorvastatin lowers augmentation index and wave reflection in hypertensive subjects: An ASCOT-LLA substudy. 18th Scientific Meeting of the European-Society-of-Hypertension/22nd Scientific Meeting of the International-Society-of-Hypertension, 14 Jun 2008 - 19 Jun 2008. 26:S458-S458. LIPPINCOTT WILLIAMS & WILKINS (1 Jun 2008). Author weblink.
  • Patel A; Chalmers J; Poulter N. ADVANCE: action in diabetes and vascular disease. 15th Meeting of the European-Society-of-Hypertension, 17 Jun 2005 - 21 Jun 2005. 19:S27-S32. NATURE PUBLISHING GROUP (1 Jun 2005). Author weblink DOI.
  • Jafar TH; Islam M; Poulter N; Hatcher J; Schmid C; Levey AS; Chaturvedi N. Children in south Asia have higher body mass adjusted blood pressure levels than Caucasian children in the United States - A comparative study. 20th Annual Meeting of the American-Society-of-Hypertension. 18:109A-109A. (May 2005).
  • Sharp A; Thom S; Francis D; Hughes A; Stanton A; Zambanini A; O'Brien E; Lyons S; et alByrd S; Poulter N; Sever P; Mayet J. Ethnicity and left ventricular diastolic function in hypertension: An ASCOT substudy. Annual Scientific Conference of the British-Society-Promoting-Cardiovascular-Health, 24 Apr 2006 - 27 Apr 2006. 92:A34-A34. B M J PUBLISHING GROUP (1 May 2006). Author weblink.
  • Sever PS; Dahlof B; Poulter N; Wedel H; ASCOT Steering Comm; ASCOT Investigators. Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): Results in the subgroup of patients with diabetes. 54th Annual Scientific Session of the American-College-of-Cardiology. 43:529A-529A. (3 Mar 2004).
  • Poulter N; Chalmers J; Patel A. What will the advance trial tell us that we don't already know?. 15th European Meeting on Hypertension, 17 Jun 2005 - 21 Jun 2005. 23:S407-S407. LIPPINCOTT WILLIAMS & WILKINS (1 Jun 2005). Author weblink.
  • Sharp A; Mayet J; Francis D; Hughes A; Stanton A; Kyd P; Zambanini A; Poulter N; et alSever P; Thom S. The effect of ethnicity on BNP levels in hyplkiension - An ASCOT sub-study. Annual Scientific Conference of the British-Society-Promoting-Cardiovascular-Health. 92:A49-A49. (May 2006).
  • Sharp A; Thom S; Hughes A; Francis D; Stanton A; O'Brien E; Fitzgerald D; Shields D; et alPoulter N; Sever P; Mayet J. Black hypertensives have significantly lower B-Natriuretic peptide levels than South Asians or Whites. 54th Annual Scientific Session of the American-College-of-Cardiology. 45:381A-381A. (1 Feb 2005).
  • Sharp A; Thom S; Francis D; Hughes A; Stanton A; Zombanini A; O'Brien E; Lyons S; et alLang C; Byrd S; Poulter N; Sever P; Mayet J. The ability of tissue Doppler echocardiography to predict future cardiovascular events in a hypertensive population: An ASCOT substudy. Annual Scientific Conference of the British-Society-Promoting-Cardiovascular-Health, 24 Apr 2006 - 27 Apr 2006. 92:A34-A35. B M J PUBLISHING GROUP (1 May 2006). Author weblink.
  • Sever PS; Poulter NR; Chang C-L; Thom SA; Hughes AD; Welsh P; Sattar N. The Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT): Testing C-Reactive Protein at Baseline and on-Treatment as an Independent Predictor of Cardiovascular Outcomes. American-Heart-Association Scientific Sessions 2010 on Resuscitation Science Symposium, 13 Nov 2010 - 17 Nov 2010. 122:2219-2219. LIPPINCOTT WILLIAMS & WILKINS (23 Nov 2010). Author weblink.
  • Poulter NR. OPTIMAL EVIDENCE-BASED CARDIOVASCULAR PROTECTION WITH PERINDOPRIL/AMLODIPINE COMBINATION. 20th Annual Meeting of the European-Society-of-Hypertension, 18 Jun 2010 - 21 Jun 2010. 28:E611-E612. LIPPINCOTT WILLIAMS & WILKINS (1 Jun 2010).
  • Robinson T; Bulpitt CJ; Ford GA; Jagger C; Knight J; Markus HS; Mistri AK; Potter JF; et alPoulter NR. CONTINUE OR STOP POST-STROKE ANTIHYPERTENSIVES COLLABORATIVE STUDY (COSSACS): MAIN RESULTS. 20th Annual Meeting of the European-Society-of-Hypertension, 18 Jun 2010 - 21 Jun 2010. 28:E234-E234. LIPPINCOTT WILLIAMS & WILKINS (1 Jun 2010). Author weblink.
  • Plutzky J; Poulter NR; Falahati A; Toft AD; Davidson MH. Plasminogen Activator Inhibitor-1 is Reduced by the Once-Daily Human Glucagon-Like Peptide-1 Analog Liraglutide When Used in the Treatment of Type 2 Diabetes. 82nd Scientific Session of the American-Heart-Association, 14 Nov 2009 - 18 Nov 2009. 120:S397-S397. LIPPINCOTT WILLIAMS & WILKINS (3 Nov 2009). Author weblink.
  • Lindgren P; Eriksson J; Buxton M; Kahan T; Poulter NR; Dahlof B; Sever PS; Wedel H; et alJonsson B. The Economic Consequences of Non-Adherence to Lipid-Lowering Therapy: Results From the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). 82nd Scientific Session of the American-Heart-Association, 14 Nov 2009 - 18 Nov 2009. 120:S484-S485. LIPPINCOTT WILLIAMS & WILKINS (3 Nov 2009).
  • Prieto-Merino D; Gupta AK; Dobson J; Chang CL; Mastorantonakis S; Sever PS; Dahlof B; Wede H; et alPocock S; Poulter NR. ASCORE: AN UP-TO-DATE CARDIOVASCULAR RISK SCORE FOR HYPERTENSIVE PATIENTS REFLECTING CONTEMPORARY CLINICAL PRACTICES DEVELOPED USING THE ASCOT TRIAL DATABASE. 19th European Meeting on Hypertension, 12 Jun 2009 - 16 Jun 2009. 27:S315-S315. LIPPINCOTT WILLIAMS & WILKINS (1 Jun 2009). Author weblink.
  • Poulter NR. BLOOD PRESSURE AND GLUCOSE CONTROL IN DIABETIC SUBJECTS: NEW ANALYSES FROM ADVANCE. 19th European Meeting on Hypertension, 12 Jun 2009 - 16 Jun 2009. 27:S290-S290. LIPPINCOTT WILLIAMS & WILKINS (1 Jun 2009). Author weblink.
  • Plutzky J; Garber A; Toft AD; Poulter NR. Meta-analysis demonstrates that liraglutide, a once-daily human GLP-1 analogue, significantly reduces lipids and other markers of cardiovascular risk in type 2 diabetes. 45th Annual Meeting of the European-Association-for-the-Study-of-Diabetes, 30 Sep 2009 - 2 Oct 2009. 52:S299-S300. SPRINGER (1 Sep 2009). Author weblink.
  • Poulter NR; Chang CL; Dahlof B; Gupta AK; Sever PS; Wedel H; ASCOT Investigators. Evaluating the efficacy of the stepped-care anti-hypertensive strategies used in the Anglo-Scandinavian Cardiac Outcomes Trial BP Lowering Arm (ASCOT-BPLA). 18th Scientific Meeting of the European-Society-of-Hypertension/22nd Scientific Meeting of the International-Society-of-Hypertension. 26:S10-S10. (Jun 2008).
  • de Galan BE; Chalmers J; Perkovic V; Ninomiya T; Pillai A; Patel A; Cass A; Macmahon S; et alNeal B; Mogensen C-E; Marre M; Harrap SB; Poulter NR; Cooper ME; Mancia G. Renoprotection with perindopril-indapamide below current recommended blood pressure targets in patients with type 2 diabetes mellitus: Results of the ADVANCE trial. 18th Scientific Meeting of the European-Society-of-Hypertension/22nd Scientific Meeting of the International-Society-of-Hypertension, 14 Jun 2008 - 19 Jun 2008. 26:S189-S189. LIPPINCOTT WILLIAMS & WILKINS (1 Jun 2008). Author weblink.
  • Gupta AK; Dahlof B; Dobson J; Sever PS; Wedel H; Poulter NR; Anglo-Scandinavian Cardiac Outcome. Determinants of new-onset diabetes among 19,257 hypertensive patients randomized in the Anglo-Scandinavian Cardiac Outcomes Trial-blood pressure lowering arm and the relative influence of antihypertensive medication. 21st Scientific Meeting of the International-Society-of-Hypertension/5th Asian-Pacific Congress of Hypertension/29th Annual Scientific Meeting of the Japanese-Society-of-Hypertension. 31:982-988. (May 2008).
  • Lindgren P; Buxton M; Kahan T; Poulter NR; Dahlof B; Sever PS; Wedel H; Jonsson B; et alASCOT Trial Invest. An amlodipine-based regimen is cost-effective compared to an atenolol-based regimen: Results from the Anglo-Scandinavian cardiac outcomes trial. 17th European Meeting on Hypertension. 25:S137-S137. (Jun 2007).
  • Gupta AK; Poulter NR; Dahlot B; Sever PS; Wedel H. Role of metabolic syndrome, independent of its components, in prediction of cardiovascular outcomes in hypertensive patients of ASCOT- BPLA. 56th Annual Scientific Session of the American-College-of-Cardiology, 24 Mar 2007 - 27 Mar 2007. 49:417A-417A. ELSEVIER SCIENCE INC (6 Mar 2007). Author weblink.
  • Poulter NR; Chang CL; Sever PS; Dahlot B; Hans W. The impact of age on blood pressure reduction due to atenolol and amlodipine in the blood-pressure lowering arm of the anglo-scandinavian cardiac outcomes trial. 56th Annual Scientific Session of the American-College-of-Cardiology. 49:371A-371A. (6 Mar 2007).
  • Gupta AK; Poulter NR; Dahlof B; Marro JE; Sever PS; Wedel H. Determinants of new onset diabetes among hypertensive patients randomised in the ASCOT-BPLA trial. 21sth Scientific Meeting of the International-Society-of-Hypertension/5th Asian-Pacific Congress of Hypertension/29th Annual Scientific Meeting of the Japanese-Society-of-Hypertension, 15 Oct 2006 - 19 Oct 2006. 24:43-43. LIPPINCOTT WILLIAMS & WILKINS (1 Dec 2006). Author weblink.
  • Poulter NR. Hypertension guidelines: An international comparison. 21sth Scientific Meeting of the International-Society-of-Hypertension/5th Asian-Pacific Congress of Hypertension/29th Annual Scientific Meeting of the Japanese-Society-of-Hypertension, 15 Oct 2006 - 19 Oct 2006. 24:17-17. LIPPINCOTT WILLIAMS & WILKINS (1 Dec 2006). Author weblink.
  • Chang CL; Poulter NR; Chapman N; Dahlof B; Sever PS; Wedel H. The effect on blood pressure and lipid profiles of doxazosin GITS as a third-line agent in the ASCOT-BPLA trial. 21sth Scientific Meeting of the International-Society-of-Hypertension/5th Asian-Pacific Congress of Hypertension/29th Annual Scientific Meeting of the Japanese-Society-of-Hypertension, 15 Oct 2006 - 19 Oct 2006. 24:64-64. LIPPINCOTT WILLIAMS & WILKINS (1 Dec 2006). Author weblink.
  • Collier DJ; Caulfield MJ; Poulter NR; Dahlof B; Wedel H; Sever PS. Did older or younger patients benefit more from amlodipine based vs atenolol based therapy in ASCOT-BPLA?. 79th Annual Scientific Session of the American-Heart-Association, 12 Nov 2006 - 15 Nov 2006. 114:896-896. LIPPINCOTT WILLIAMS & WILKINS (31 Oct 2006). Author weblink.
  • Chang CL; Chapman JN; Sever PS; Dahlof B; Wedel H; Poulter NR. The effect on blood pressure and lipid profiles of doxazosin gits as a third-line antihypertensive agent in the anglo-Scandinavian cardiac outcomes trial (ASCOT). 16th European Meeting on Hypertension. 24:S3-S4. (Jun 2006).
  • Poulter NR; Dahlof B; Sever PS; Wedel H; Collier D. Impact of atorvastatin on cardiovascular events in 2440 men and women aged 65 years and above: Evidence from the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA). International Stroke Conference. 37:695-695. (Feb 2006).
  • Sever PS; Dahlof B; Poulter NR; Wedel H. Anglo-scandinavian cardiac outcomes trial: Lipid lowering arm (ASCOT LLA) revisited: Interaction of antihypertensive and lipid lowering therapy. 78th Annual Scientific Session of the American-Heart-Association. 112:U188-U188. (25 Oct 2005).
  • Primatesta P; Poulter NR. Implications of an obesity epidemic on BP levels in England. 14th European Meeting on Hypertension. 22:S288-S289. (Jun 2004).
  • Primatesta P; Poulter NR. Lipid levels and treatment in England and Scotland. 25th Congress of the European-Society-of-Cardiology. 24:242-242. (Aug 2003).
  • Primatesta P; Falaschetti E; Poulter NR. Birthweight and blood pressure in children: Does the association exists?. 18th Annual Scientific Meeting of the American-Society-of-Hypertension. 16:216A-217A. (May 2003).
  • Primatesta P; Poulter NR. England 2000: Hypertension affects 80% of older people. 19th Meeting of the International-Society-for-Hypertension/12th European-Society-of-Hypertension Meeting, 23 Jun 2002 - 27 Jun 2002. 20:S253-S253. LIPPINCOTT WILLIAMS & WILKINS (1 Jun 2002). Author weblink.
  • POULTER NR. BEYOND BLOOD-PRESSURE. 8:S3-S8. NATURE PUBLISHING GROUP (1 Sep 1994). Author weblink.
  • POULTER NR. FROM STEPPED CARE TO TAILORED THERAPY. ZESTORETIC INVESTIGATORS MEETING ON HYPERTENSION - CONTROL BY COMBINATION : FOCUS ON LISINOPRIL-HYDROCHLOROTHIAZIDE. 5:17-22. (Dec 1991).
  • POULTER NR. TREATMENT OF HYPERTENSION - A CLINICAL EPIDEMIOLOGISTS VIEW. MEETING ON ACE ( ANGIOTENSIN-CONVERTING ENZYME ) INHIBITION - PRESENT AND FUTURE : THE ROLE OF RAMIPRIL, 12 Oct 1990 - 13 Oct 1990. 18:S35-S38. LIPPINCOTT-RAVEN PUBL (1 Jan 1991). Author weblink DOI.
Share this on Delicious
Tweet this
Digg this
Stumble this
Share this on Facebook